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3I. IntroductioD
In 1996, California and Arizona passed medical marijuana initiatives with
55.6%' and 65.4%2 of the votes respectively. The elections stunned federal, state
and local leaders, who convened in an emergency session of the Senate Judiciary
Committee to determine what had happened. These leaders maintained that
the Arizona and California voters had been duped by pro drug legalization
advocates masquerading as compassionate groups seeking to comfort the sick
and dying. Government leaders maintained that systems were in place to deal
with medicines and that misguided voters should not subvert these safeguards.
The government leaders failed to recognized that in the case of Schedule I
drugs, these systems had failed. The current political, legal, and administrative
syste~n in the United States does not provide a method to determine whether
Schedule I substances are medically benecial. Modern science does not accept
anecdotal evidence; it requires rigorous and exhaustive testing before a drug
is deemed safe and eective. Yet the federal government has thwarted any
attempt to perform this necessary scientic testing. Therefore, according to
the scientic standards in the United States, nobody knows whether marijuana
possesses medically benecial properties that outweigh its risks.3 On the other
hand, for the same reasons, nobody knows whether marijuana is not medically
benecial. For the past twenty ve years, the federal government has refused to
allow this question to be answered.
'California Secretary of State web site, 1996 Election Results,
<http://Vote96.ss.ca.gov/Vote96/html/vote/prop/page.96 1218083528.html>
(January 14, 1998).
2Arizona Secretary of State web site, Unocial Election Results, <http://sosaz.corn/results/l996general/FEN5600.htm>,
(January 14, 1998).
3Marinol, a drug approved by the FDA is a synthetic form of THC, the pri-
mary active substance in marijuana. Logic dictates that if Marinol has medical
benets, marijuana would have medical benets. The debate then centers on
whether the risks associated with raw marijuana outweigh the benets.
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In this paper, I take the position that according to contemporary scientic
standards in the United States, marijuana has not been shown to be medically
benecial. I also takes the position that even if marijuana has medically bene-
cial properties, the current syctem in the United States oers no method for
proving such a fact in a scientically acceptable manner. Therefore, patients,
physicians, and other advocates who believe that marijuana is medically eec-
tive, have no alternative but to pursue alternative methods, such as state voter
initiatives, to achieve their goal. This strategy has proven eective in pressur-
ing the federal government to relent and allow scientic testing of marijuana
to nally answer the question of whether marijuana has medical benets. The
ultimate goal, for the purposes of this paper, is to answer the medical mari-
juana question in a denitive manner. If marijuana is shown to be benecial,
it should be absorbed into the proper systems regulated by the Food and Drug
Administration.
This paper briey chronicles the eorts of marijuana activists at the federal
level. Then it analyzes the text, implementation and subsequent developments
of the California and Arizona initiatives passed by the voters in 1996, with the
goal of helping future initiative drafters learn from the failures and successes
of these initiatives. Finally, this paper critically analyzes medical marijuana
initiatives currently being pursued throughout the country.
H. Relevant Federal Legislation
In order to understand marijuana's recent history, as well as the nuances
of the state initiatives, it is necessary to have at least a cursory understanding
of the Food Drug and Cosmetics Act (FDCA) and the Controlled Substances
Act (CSA), and how the two interact when a drug classied as a controlled
substance is involved. Understanding how the two acts t together is not an
easy task. The interrelationship between the two Acts is far from clear.4
4National Organization For the Reform of Marijuana Laws (NORML) v.
DEA, 559 F.2d 735.
750 note 65, 118 U.S. App. D.C. 114 (D.C. Cir. 1977).
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A. The Food Drug and Cosmetics Act (FDCA)
The Food Drug and Cosmetics Act (FDCA) is a sweeping legislation that
regulates just about any substance that goes on or into the bodies of humans
and animals.5 As it relates to drugs, the FDCA is directed mainly at keeping
unsafe drugs out of interstate commerce. Because it is more like a consumer
protection statute than a criminal statute, the FDCA focuses primarily on issues
of distribution as opposed to possession. It does not prohibit the possession of
unapproved drugs.
The FDCA s regulation of drugs begins with its denition of a drug. A drug
is (a) any article recognized by an ocial compendium6 such as the United
States Pharmacopoeia; (b) any article intended to diagnose, cure, mitigate,
treat, or prevent disease in humans or animals; (c) any article (other than
food) that is intended to aect the structure or function of the body; and (d)
components of any article in the rst three categories.7 No new drug may be
introduced or delivered into interstate commerce without the approval of the
Food and Drug Administration
(FDA).8
5This discussion is intended to give a brief sketch of the drug approval pro-
cess and give the reader a feel for how the FDA gets its authority to regulate
drugs. For a more in-depth discussion of the FDA approval process, see Veron-
ica Henry, Problems with Pharmaceutical regulation in the United States, 14
Journal of Legal Medicine 617 (1993).
621 U.S.C.A. x33216).
~2l U.S.C.A. x321(g).
~2l U.S.C.A. xx331(d), 355(a).
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While nobody would question the fact that marijuana is a drug according
to this denition,9 one may wonder why marijuana would fall into the new
drug category considering it has been used as medicine for centuries.'0 The
term new drug is dened as any drug that does not meet one of the following
two exemptions. First, drugs that are generally recognized by experts as safe
and eective for the use described in the labeling are exempted. Second, drugs
subject to the Food and Drug Act of June 30, 1962 are not considered new drugs
if their labels have not changed with respect to uses of the drug.'2 Some experts
argue that marijuana is safe and eective,13 but Congress has determined that
it lacks an accepted medical use or level of safety by virtue of its designation as
a Schedule I substance.'4
In order to receive approval by the FDA of a new drug, one must rst perform
rigorous clinical trials of the drug. The process begins with the submission of
an Investigational New Drug Application (IND) to the FDA, which must occur
before clinical testing can begin.'5 Because the FDCA prohibits the introduction
into interstate commerce of unapproved new drugs, and one cannot realistically
perform clinical trials on a drug without violating the prohibition, the FDCA
creates an exemption for new drugs intended for investigational use.'6
9At least for medical uses, marijuana is intended to be used as a drug.
'Robert C. Clarke & David W. Pate, Medical Marijuana, in Hemp Today
303, 306 (Ed Rosenthal ed., 1994).
21 U.S.C.A. x321(p).
1221 U.S.C.A. x321(p)(l).
3~ Ed Rosenthal, Introduction, in Hemp Today, and Robert C. Clarke &
David W. Pate, Medical Marijuana in Hemp Today 299-309 (Ed Rosenthal ed.,
1994).
'~2l C.F.R. x3 12.20.
621 U.S.C.A. x355(i).
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The new drug sponsor must then perform three stages of human clinical
evaluations for safety and ecacy.'7 These three phases last approximately six
years.'8 After the clinical trials, the sponsor submits a New Drug Application
(NDA), which must contain reports of all investigations and all other informa-
tion pertinent to the drug, to the FDA.'9 When the FDA approves a NDA, it
classies it as either a prescription drug or a non prescription drug.20
Once a drug's NDA is approved, the FDCA no longer prohibits its distri-
bution. However, the FDCA still regulates all drugs (both approved new drugs
and exempted old drugs), as well as food and cosmetics, through restrictions
on misbranded and adulterated substances.2' While the terms misbranded and
adulterated seem narrow, these two words provide the basis for an entire reg-
ulatory structure. For example, a prescription drug dispensed without a valid
prescription is deemed to be misbranded. In fact, a manufacturer, who markets
its drug for a use other than that for which the FDA approved it, misbrands
the drug.22 Furthermore, any distribution of material distributed by the man-
ufacturer that describes the use of a drug is deemed labeling by the FDCA.23
Therefore, falsehoods in such materials would constitute misbranding.24
'7See Veronica Henry, Problems with Pharmaceutical Regulation in the United States,
14 Journal of Legal Medicine 617, 621 (1993).
'Veronica Henry, Problems with Pharmaceutical Regulation in the United States,
14 Journal
of Legal Medicine 617, 621 (1993).
'~21 C.F.R. x3 14.50.
2021 U.S.C.A. x353(b)(1)(B); $~ National Nutritional Foods Association v.
Weinberger, 512 F.2d 688, 699 (2nd Cir. 1975) (ruling that the FDA has the
power to determine which products are prescription drugs).
2121 U.S.C.A. x331(a)-(c).
225ee Richard A. Merrill, The Architecture of Government Regulation of Medical Products,
82 Virginia Law Review 1753, 1853-4 (1996).
2321 U.S.C.A. x 321(m)-(n); Kordel v. Untied States 335 U.S. 345, 349-50
(1948) (ruIini.~ tku pamphlets and other materials describing a drug constitute
labeling regardless of whether iK> ire
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The FDA has used this misbranding restriction to institute a comprehensive
set of guidelines on manufacturer advertising.25
When an individual distributes an unapproved new drug, or a drug deemed
misbranded or adulterated, federal courts have the authority to enjoin such
distribution.26 Furthermore, the person who distributes the drug is subject to
imprisonment for up to one year and nes up to $1,000 for a rst oense and
three years and $10,000 for a subsequent oense.27
B. The Controlled Substances Act (CSA)
The Comprehensive Drug Abuse Prevention and Control Act of 1970, better
known as the Controlled Substances Act (CSA) categorizes substances that pose
a danger of abuse and dependence into ve schedules, according to the level of
danger for abuse and dependence the substance poses.28 A substance placed
in any of the schedules is considered to be a controlled substance. Marijuana
is a Schedule I drug, which means that it has a high potential for abuse, no
currently accepted medical use in treatment in the United States, and is not
accepted as safe, even under medical supervision.29 Examples of other Schedule
I drugs include peyote, PCP, heroin, and LSD.30 A Schedule II drug has a high
potential for abuse, has a currently accepted medical use in the United States
with severe restrictions, and poses a danger of severe
physically attached to the product).
2421 U.S.C.A. x 33 1(a).
2521 C.F.R. x 202.1.
2621 U.S.C.A. x332(a).
2721 U.S.C.A. x333(a).
2821 U.S.C.A. x812(b)(1).
2921 U.S.C.A. x812(b)(1); 21 C.F.R. x1308.11 Schedule I (d)(19)
~~21 C.F.R. x1308.11 Schedule I.
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psychological or physical dependence.3' Examples of Schedule H drugs in-
clude cocaine and opium?2 A Schedule 111 drug has a lower potential for abuse
compared to Schedule I and H drugs, a currently accepted medical use in the
United States, and a moderate to low risk of physical dependence or a high risk
of psychological dependence.33 Examples of Schedule HI drugs include anabolic
steroids and certain diluted mixtures of codeine.34 A Schedule IV drug has a
relatively low potential for abuse compared to Schedule HI drugs, a currently
accepted medical use in the United States, and a potential for limited physi-
cal or psychological dependence compared to Schedule III drugs.35 Examples of
Schedule IV drugs include both components of the diet drug Phen fen (phen-
termine and fenuramine).36 A Schedule V drug has a low potential for abuse
and physical or psychological dependence relative to Schedule IV drugs, and
an accepted medical use in the United States.37 Examples of Schedule V drugs
include further diluted mixtures of codeine.38
The Controlled Substances Act authorizes the Attorney General to either
reschedule a drug or remove it from scheduling after taking into account its
potential for abuse, its potential for dependency, and scientic knowledge of the
drug.39 The Attorney General has delegated all
~'21 U.S.C.A. x 812(b)(2).
3221 C.F.R. x1308.12 Schedule II.
~~21 C.F.R. x1308.13 Schedule III.
3621 C.F.R. x 1308.14 Schedule IV.
3821 C.F.R. x1308.15 Schedule V.
~~2l U.S.C.A. x811(c).
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authority derived from the CSA to the Administrator of the Drug Enforce-
ment Administration (DEA),40 who may delegate its authority to subordinates
in the DEA.4' Therefore, the DEA has the legal authority to reschedule or de-
schedule a drug. While the DEA has the formal legal authority to schedule
a drug, the FDA retains signicant power over the drug scheduling process.
The Attorney General, Secretary of Health and Human Services, or an inter-
ested party may le a petition to reschedule a controlled substance.42 Once a
petition is led, the DEA must request scientic and medical evaluations from
the Secretary of Health and Human Services (Secretary), along with the Sec-
retary's recommendation as to how the drug should be scheduled and hold a
public hearing on the matter.43 The Secretary has delegated this responsibility
to the FDA~ These scientic and medical evaluations are binding on the DEA.45
Because a Schedule I drug by denition does not have an acceptable medical
use in the United States, if the FDA recognizes an acceptable medical use, the
DEA may no longer keep a drug in Schedule I. Furthermore, the DEA may not
control a drug at all if the FDA recommends that the drug not be controlled.
In eect, unless the FDA does not make a recommendation, the DEA merely
has authority to determine in which schedule to place a drug, consistent with
the FDA's scientic and medical evaluations.
4028 C.F.R. 0.100.
~'28 C.F.R. 0.104.
4221 U.S.C.A. 811(a).
~~2l U.S.C.A. 811(b).
451d.
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This preceding explanation is a bit simplistic and possibly misleading be-
cause if an international treaty or obligation, to which the United States has
adhered, requires control of a certain drug, 21 U.S.C.A. x811(d) states that
the Attorney General (who's authority is delegated to the DEA) shall sched-
ule the drug as she deems t, without regard to the recommendations of the
FDA. Since most substances covered by the CSA are controlled by treaties, a lit-
eral reading would eectively void the power Congress gave to the Secretary. In
National Organization For the Reform of Marijuana Laws (NORML) v. DEA46
the court found that Congress never intended to bestow such discretion on the
DEA. Instead, the court found, the DEA may overrule the FDA only to the
extent necessary to satisf~,' the treaty obligations of the United States.47 Al-
though the Secretary of Health and Human Services and the FDA maintain
signicant power.
The question then becomes, how does one access a Schedule I drug, not
yet approved by the FDA, to perform the clinical testing necessary for FDA
approval of a New Drug Application? To distribute a Schedule I or II controlled
substance, one must obtain DEA registration.48 The DEA has broad discretion
in terms of whose registration application it approves.49 For clinical research,
one must rst receive approval of an Investigational New Drug Application
(IIND) by the FDA.50 Then the researcher must submit the approved ND to
the DEA along with a statement of security provisions the researcher intends
to implement.5' The CSA requires the DEA to forward the application and
protocol to the Secretary of Health and Human Services,
46559 F.2d 735, 746, 182 U.S. App. D.C. 114 (D.C. Cir. 1977).
471d.
4821 C.F.R. 1301.11.
~~21 U.S.C.A. 823(b)
5021 C.F.R. 1301.18(b); 21 C.F.R. 312.20 (requirements foraniND).
~'21 C.F.R. 1301.18(b).
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who has ultimate authority to approve or reject the protocol. This require-
ment is moot because the Secretary has delegated this authority to the FDA,
which has already approved the protocol.52 The FDA should, however, defer to
the DEA for issues of adequate safeguards to prevent diversion of the drug.53
Once the FDA has approved the ND and the DEA has approved the research
protocol application, thus registering the applicant as an approved Schedule I
or II distributor under 21 U.S.C.A. 823, the researcher may proceed as with
any other new drug clinical trial. With a Schedule I drug, however, the re-
searcher still has a problem of access to the drug. Unless the researchers wish to
manufacture (or grow) the drug themselves (an endeavor that also requires DEA
approval54), nding a domestic source of the drug may prove dicult.55 Another
alternative is to import the drug, which requires DEA approval.56 Although not
impossible to perform, experiments involving Schedule I drugs pose greater ob-
stacles to researchers than experiments involving drugs in other schedules. In
the case of approving imports, the DEA retains sole authority to approve or
reject the application.
C. Physician Liability Under the CSA and FDCA
The two biggest issues for medical marijuana and the two Acts are how the
law applies to a patient using marijuana and how the law applies to a physi-
cian who prescribes it. The FDCA is primarily aimed at commerce involving
misbranded, adulterated, and unapproved new drugs. A
5221 C.F.R. 5lO(a)(8-l0).
~~21 C.F.R. x 1301.32(a).
~~21 C.F.R. x1301.1 8(a)(2)(vii).
For example, the only legal source for marijuana in the United States is the
National Institute on Drug Abuse. Chemist is USA's Guardian of Grass USA
Today, February 10, 1997, 3A.
5621 C.F.R. 1312.11, 1312.12, 1312.13.
See Grinspoon v. DEA, 828 F. 2d 881, 896 (1st Cir. 1987).
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drug marketed intrastate could theoretically be sold without FDA approval.58
It is not an attempt to restrict possession of a substance, or regulate physicians
or the practice of medicine.59 In other words, it regulates the availability of
drugs that a physician may prescribe, as opposed to regulating a physician's
ability to prescribe drugs. Attempts have occasionally been made to prosecute
physicians for prescribing drugs absent a legitimate patient-doctor relationship;
however, most of these prosecutions involve a physician personally distributing
a drug, as opposed to merely prescribing it.60
Case law and FDA policy, however, both indicate that the FDCA may not
regulate physicians prescribing habits within a legitimate doctor-patient rela-
tionship. For a number of years, the FDA has facilitated a personal use impor-
tation exemption that allows patients to import limited amounts of unapproved
drugs, if done so under the supervision of a physician.6' Implicit in this program
is the act of a physician prescribing, or at least supervising the use of, an unap-
proved new drug. Additionally, the FDA allows, and possibly does not have the
authority to prevent, physicians writing o-label prescriptions.62 An o-I abel
prescription is one where a physician prescribes a drug for an ailment, or in a
manner, that the FDA has not approved. Such
5tSee Grinspoon v. DEA at 887.
59U.S. v. Evers, 643 F.2d 1043, 1048 (5th Cir. 1981).
60Most prosecutions were for distribution of drugs by a physician, as op-
posed to drug prescription. These cases became moot after the passage of the
Controlled Substances Act of 1970. See DeFreese v. United States, 270 F.2d
730 (5th Cir. 1959); Brown v United States, 250 F.2d 745 (5th Cir. 1958).
Physicians, however, have been prosecuted for prescribing drugs outside of a
doctor-patient relationship. Doe v. Untied States, 801 F.2d 1164 (9th Cir.
1986).
61 ~g. Eric Lindemann, Importing Aids Drugs: Food and Drug Administration Policy and its Limitations.
28 Geo. Wash. J. of Int'l. L. & Econ. 133 140-142 and fn 8, 1994.
6237 Fed. Reg. 16,503 (1972). See also, Lars Noah, Constraints on the O-Label Uses of Prescription Drug Products,
16 J. Prods. & Toxics Liab. 139 (1994).
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activity is not only common, but frequently represent[s] acceptable, some-
times even essential, clinical practice.63 The FDA draws a clear distinction be-
tween prescribing, and promoting or distributing drugs.64 It recognizes that it
is powerless to sanction a physician for prescription practices, and is limited
in its statutory mandate to controlling the actual drug through restricting its
movement in interstate commerce.65
Conversely, a physician who prescribes a Schedule I drug without permission
from the DEA is subject to prosecution. First time oenders are subject to one
year in prison and a $25,000 ne.66 Furthermore, the physicians may lose their
registrations permitting them to prescribe any controlled substances.67
While most people understand that the CSA prohibits the possession and
distribution of certain kinds of drugs, it is important to understand how the
statute aects drugs in the medical realm and where the DEA derives its author-
ity to impose sanctions on physicians for their prescribing practices. The CSA
generally restricts possession of a controlled substance without a prescription.68
It does not, however, authorize prescriptions for Schedule I drugs.69 For a real
life example{in the context of marijuana, a patient who wishes to lawfully use
marijuana for medical
Richard A. Merrill, The Architecture of Government Regulation of Medical Products,
82 Va. L. Rev. 1753, 1854.
See id. at fn 318.
65J~ 37 Fed. Reg. 16503 (1972), the FDA proposed regulation that would
have allowed the FDA to change a drug's labeling, restrict its distribution, or
revoke approval if o-label prescribing became a problem. The FDA recog-
nized that it could not regulate the physicians and had to eect change through
regulating the products.
6621 U.S.C.A. x842(c)(2).
6721 U.S.C.A. x824(a)(2).
6821 U.S.C.A. x844(a).
6921 U.S.C.A. x829.
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purposes needs a prescription; however, physicians are not permitted to
issue prescriptions for marijuana. Therefore, notwithstanding state laws to the
contrary, a patient who possesses marijuana, regardless of purpose, is in violation
of federal law. The only exception to this prohibition would be possession in
connection with DEA approved clinical research.70
Furthermore, under the Act, a physician may not dispense or prescribe7'
a controlled substance unless registered by the Attorney General to do so.72
Physicians who prescribe marijuana to their patients are subject to prosecution
and loss of registration to prescribe controlled substances. The DEA has also
taken the position that it may revoke the registration of physicians who recom-
mend Schedule I drugs to their patients. Although recommending would not
violate a law, the DEA claims that 21 U.S.C.A. x824(a)(4) allows it to reject
registrations for acts that violate the public interest.74 Rescinding a physician's
registration, however, for acts that do not constitute a crime and involve com-
munication with a patient may violate the physician's First Amendment right to
speech. The line between acts against public interest and free speech is unclear.
A recent district court decision indicates that recommending may be covered by
the First Amendment.75
7021 C.F.R. x1301.18.
71The Act considers prescribing a drug to be the equivalent of dispensing.
21 U.S.C.A.
802(10).
7221 U.S.C.A. xx823(f~, 844(a).
73Conant v. McCarey, 172 F.R.D. 681, 699 (N.D. CA 1997).
741d.
751d.
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If the Attorney General revokes a physician's license to prescribe controlled
substances, the Attorney General has eectively revoked a physician's ability
to prescribe drugs, because a large number of commonly prescribed drugs are
controlled substances.76 This power the DEA wields signicantly impacts any
state laws aimed at making marijuana available for medical purposes because
these laws cannot utilize the prescription process to make marijuana available
to patients while restricting it from recreational users.
III. History of Eorts at the Federal Level to gain Access to Mari-
juana for Patients Who May Benet
Soon after the CSA passed, marijuana advocates began a campaign to gain
access to marijuana for patients. Due to marijuana's unique situation, this
group could not follow the traditional avenue taken by pharmaceutical compa-
nies seeking FDA approval for their drugs. Eorts to obtain FDA approval for
a new drug take years and cost millions of dollars. To compensate these com-
panies for their time and expense, the government grants them the exclusive
right to sell their drugs for a certain number of years. In order to recoup these
costs, pharmaceutical companies sell their drugs at inated prices. Without the
exclusive right to sell the drug, competitors unburdened by these millions of
dollars in sunk costs could sell the drugs at lower prices, becoming free riders
on the original company's research.
Just as with any other drug, eorts to gain FDA approval for marijuana
would take a number of years and cost millions of dollars. Because marijuana is
a plant that can grow just about anywhere, if the FDA were to approve it as a
drug, patients would have little incentive to purchase it at inated prices from
pharmacies when they could grow their own. Consequently, pharmaceutical
companies have little incentive to incur the costs of securing FDA approval for
marijuana, especially when its approval may take market share away from drugs
that they
76~~ Cal. Att'y. Gen. Oce, Proposition 215: An Analysis, (December 20,
1996), 5.
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currently market. Medical marijuana advocates recognized this problem
and focused their original eorts at rescheduling marijuana to a Schedule that
allowed doctors to prescribe it to their patients on an individual basis. They also
attempted to allow patients access to marijuana while it remained a Schedule I
drug on a case by case basis. When they realized that marijuana would not be
rescheduled, they began to seek FDA approval. By 1996, they had failed on all
three fronts.
A. NORML v. DEA
In 1972, the National Organization for the Reform of Marijuana Laws (NORMiL)
petitioned the DEA's predecessor, the Bureau of Narcotics and Dangerous Drugs
(BNDD) to reschedule marijuana and found itself locked in litigation with an
intransigent DEA for twenty-two years. NORMIL originally requested the gov-
ernment to either remove marijuana from scheduling or alternatively reschedule
it to Schedule V. Under 21 U.S.C.A. 811, the BNDD was required to refer
the petition to the Secretary of Health, Education and Welfare (HEW), the
predecessor to the Department of Health and Human Services (HHS), for scien-
tic evaluation. The BNDD refused to accept the petition or refer it to HEW,
claiming that it had sole authority for scheduling drugs covered by international
treaties to which the United States was a party.77
NORMIL sought appellate review of BNDD's refusal to even accept their
petition for rescheduling and the court of appeals ruled that the treaty obliga-
tions did not prevent the BNDD (now the DEA) from reviewing the petition,
even ifjust to determine what the United States treaty obligations really were.78
The court remanded the case, requiring the DEA to determine
7737 Fed. Reg. 18097 (1972). See also NORMI v. Ingersol, 497 F.2d 654,
656 (D.C. Cir. 1974).
78NORMIL v. Ingersol at 661.
1816
whether international treaties allowed the DEA to place marijuana in any
other Schedules. It also ordered the DEA to seek evaluations and recommenda-
tions from HEW.79
The DEA held a hearing before Administrative Law Judge Parker to de-
termine the extent of the treaty obligations. He ruled that the DEA had the
authority to reschedule cannabis (owers and tops) and cannabis resin to Sched-
ule II, cannabis leaves to Schedule V, and it could deschedule synthetic THC. He
also ruled that the DEA should follow normal procedures relating to reschedul-
ing, including abiding by HEW's recommendations.80
The DEA Administrator rejected Judge Parker's conclusions, ruled that mar-
ijuana would remain in Schedule I, and refused to refer the petition to HEW
for recommendations.8' He maintained that 21 U.S.C.A. 20 1(d) gave him sole
discretion to schedule controlled substances and he did not have to seek rec-
ommendations from HEW.82 He argued that even if he did have to refer the
petition for rescheduling to HEW, a letter the DEA had received from the Act-
ing Assistant Secretary of Health that stated there is currently no accepted
medical use of marijuana in the United States, met that requirement.83
NORMIL appealed for the second time and the court of appeals ruled that
the DEA was bound to follow HEW's recommendations up to the point at which
they would cause a violation of an international treaty and ordered it to refer
NORML's rescheduling petition to I-IEW.84 By this time, ve years had passed
since NORMIL led its petition and the DEA had yet to take
~NORML v. Ingersol at 661.
80NOv~L v. DEA, 559 F.2d 735, 742 (D.C. Cir. 1977).
8l4Q Fed. Reg. 44164, 44168 (1975).
824O~J~4j~ v. DEA, 559 F.2d 735, 743 (D.C. Cir. 1977).
83NORML v. DEA, 559 F.2d 735, 742 (D.C. Cir. 1977).
84NORMIL v. DEA, 559 F.2d 735, 746-7 (D.C. Cir. 1977).
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action on its merits or refer it to HEW. The court ordered the DEA to obtain
separate recommendations from HEW for cannabis and cannabis resin, leaves,
seeds capable of germination, and synthetic THC.85 It chastised the DEA for
relying on the letter, and, noting a HEW report on potential therapeutic aspects
of marijuana, ordered the DEA to hold a formal hearing on the question of
marijuana's medical potential.86 Contrary to the court's order, however, HEW
did not make separate evaluations and merely recommended that marijuana
remain in Schedule 1.87
NORML appealed for the third time, and for the third time the DEA Admin-
istrator was reversed. The court chastised the DEA and HEW for not following
its order to evaluate the four separate classications of marijuana and implied
that the DEA had attempted to skirt the spirit of its previous decision.88 The
Court again ordered the DEA to refer the petition to HEW's successor HHS for
scientic and medical ndings for each of the four classications.89
The FDA, under its authority from IfHS, reviewed NOR.ML's petition and
concluded that all portions of marijuana should remain in Schedule 17' After
the FDA's recommendation, notwithstanding the CSA's requirement for a public
hearing, the DEA did not hold a hearing on
85NORMIL v. DEA, 559 F.2d 735, 749 (D.C. Cir. 1977).
86NORML v. DEA, 559 F.2d 735, 757 (D.C. Cir. 1977).
87In the Matter of Marijuana Rescheduling Petition, Opinion and Recom-
mended Ruling, Findings of Fact, Conclusions of Law and Decision of Adminis-
trative Law Judge Francis L. Young, September 6, 1988, No. 86-22, accessed at
<http ://mojo.calyx.notl|olsen/MEDICAL/YOUNG/young 1.html> (Jan-
uary 10, 1998).
88NORML v. DEA No. 79.1660, unpublished D.C. Circuit order led Octo-
ber 16, 1980. cited in In the Matter of Marijuana Rescheduling Petition at 3.
89NORML v. DEA No. 79.1660, unpublished D.C. Circuit order led October
16, 1980. cited in In the Matter of Marijuana Rescheduling Petition at 3.
~47 Fed. Reg. 28141 (1982).
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the petition for six years. By this time, NORMI. had modied its petition,
seeking only that marijuana be moved to schedule II. The Administrative Law
Judge presiding over the hearing, Francis L. Young, found that a respectable
minority of doctors accepted marijuana as having a medical use in treating
cancer patients, multiple sclerosis, and hyperparathyroidism.9' He cited copi-
ous examples of marijuana's usefulness in treatment and concluded that any
decision claiming that marijuana had no acceptable medical use in the United
States would be unreasonable, arbitrary, and capricious.92 He concluded that
marijuana was medically benecial and recommended that the DEA reschedule
marijuana to Schedule H.93
The DEA administrator, for the second time, rejected the ndings of an ad-
ministrative law judge, in this case claiming that the anecdotal evidence Judge
Young relied on did not meet the requirements of scientic evidence.94 He ap-
plied an eight part test previously developed by
9'In the Matter of Mariluana Rescheduling Petition at 29, 34, 54-5.
In the Matter of Marijuana Rescheduling Petition at 34.
93In the Matter of Marijuana Rescheduling Petition at 67.
9454 Fed. Reg. 53767 (1989)
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the DEA to determine whether marijuana had an accepted medical use in
the United States,95 and on the basis of that test denied NORML's petition.
NORMiL appealed for the fourth time and the court for the fourth time
reversed the DEA, calling its eight part test arbitrary and capricious.96 It noted
that at least three of the eight factors in the DEA's test could not possibly be met
by a Schedule I drug, creating a catch 22 where no Schedule I substance could
ever be rescheduled because it would fail the test by virtue of its classication
as a schedule I drug.97 The DEA Administrator issued a new ve part test that
omitted the three impossible factors, and ruled that because marijuana did not
meet this test either, it would remain in Schedule 1.98 He also noted that in the
future, anecdotal evidence of
95The eight part test required a drug to meet the following requirements to
be considered to
have an accepted medical use in treatment in the United States:
1. Scientically determined and accepted knowledge of its chemistry;
2. The toxicology and pharmacology of the substance in animals;
3. Establishment of its eectiveness in humans through scientically
designed clinical trials;
4. General availability of the substance and information regarding
the substance and its use;
5. Recognition of its clinical use in generally accepted pharmacopeia,
medical references, joumals or textbooks;
6. specic indications for the treatment of recognized disorders;
7. Recognition of the use of the substance by organizations or associa-
tions of physicians;
8. Recognition and use of the substance by a substantial segment of the
medical practitioners in the United States. 54 Fed. Reg. 53767, 53783 (1989).
96Alliance for Cannabis Therapeutics et al. v. DEA, 930 F.2d 936, 940
(1991).
97Numbers 4, 5 and 8 were deemed impossible for a Schedule I drug to meet.
Alliance for Cannabis Therapeutics et al. v. DEA, 930 F.2d 936, 940 (1991).
98The ve part test includes the following factors:
1. The drug's chemistry must be known and reproducible;
2. There must be adequate Safety Studies;
3. There must be adequate and well-controlled studies proving e-
cacy;
4. The drug must be accepted by qualied experts
5. The scientic evidence must be widely available.
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eectiveness and opinions of practitioners would not be considered by the
DEA in evaluating rescheduling petitions 7' NORML appealed for the fth time
and lost.'~
NORMIL spent twenty-two years attempting to reschedule marijuana. The
DEA spent sixteen years avoiding the petition before it ever held a hearing on its
merits; then it rejected the administrative law judge's recommendations. Four
times, the DEA was overturned by appellate courts, sometimes with criticism
for acting in bad faith. This experience led marijuana advocates to conclude
that at the federal level politics and medicine were inseparable and the politics
would prevail.
B. The Compassionate ND Program
During these years, marijuana advocates also pursued other avenues to al-
low patients and physicians to obtain marijuana on a case by case basis for
treatment. In the late 1970's, they succeeded in persuading the FDA to create
a single patient ND program also known as the compassionate ND program,
which allowed approved physicians to receive and dispense marijuana to their
patients. The FDA administered the program and evaluated the applications,
and the National Institute on Drug Abuse (NIDA) provided the marijuana.'02
To comply with the
57 Fed. Reg. 10499, 10506 (1992).
~S7 Fed. Reg. 10499, 10506 (1992).
'00Alliance for Cannabis Therapeutics et al. v. DEA, 15 F.3d 1131 (1994).
Lester Grinspoon, M.D. & James B. Bakalar, ID, Marihuana as Medicine: A Plea for Reconsideration
JAMA, June 1995 ~~ised at the Schaer Library of Drug Policy web site <http
://www.druglibrary.org/schaerlhemp/medical/grinjama.htm> (January 10, 1998).
'02Declaration of Daniel A. Spyker, Ph.D., M.D., Human v. FDA, No. 93-
0237 NHJ (June 13, 1993), accessed at <http://mojo.calyxnetkolsen/M1EDlCAL/spyker.html>
(January 10.
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Controlled Substances Act, the physicians also had to obtain DEA registra-
tion before they could obtain the marijuana from NIDA.'03
As the AIDS epidemic increased, more patients began applying to the pro-
gram. In response, the federal government discontinued the program, citing its
opposition to illegal drugs and the lack of persuasive research to indicate the
program's value.'04 NIDA would continue to supply patients already receiving
marijuana, but patients who had been approved by the FDA but not yet by
the DEA were excluded.'05 Due to attrition, the program currently provides
marijuana to eight patients. 06
By 1992, the compassionate ND program had been discontinued and the
futility of NORMIL's petition to reschedule marijuana was becoming appar-
ent. Marijuana would remain forbidden unless its advocates could obtain FDA
approval. On the other hand, the AIDS epidemic coupled with evidence that
marijuana could help alleviate the nausea and weight loss associated with AIDS
had increased the support for access to marijuana. These factors led to renewed
attempts at clinical testing.
'03Id.
'04Lester Grinspoon, M.D. & James B. Bakalar, ID, Marihuana as Medicine: A Plea for Reconsideration
JAMA, June 1995 ~~at the Schaer Library of Drug Policy web site <http://www.druglibrary.org/schaer/hemp/medicallgrinjania.htm>
(January 10, 1998); Peter Gwynne, Trials of Marijuana's Medical Potential Languish as Government Just Says No,
The Scientist Vol:9, No.23, November 27, 1995, 3, accessed at The Scientist web
site <http://www.the-scientist.library.upenn.edulyrl 995/nov/smoke 95112.html>
(April 29, 1998).
'05Declaration of Daniel A. Spyker, Ph.D., M.D., Human v. FDA, No. 93-
0237 NHJ (June 13, 1993), accessed at <http://mojo.calyxnet/|olsen/MEDICAL/spyker.html>
(January 10, 1998).
'06Lester Grinspoon, M.D. & James B. Bakalar, ID, Marihuana as Medicine: A Plea for Reconsideration
JAMA, June 1995 accessed at the Schaer Library of Drug Policy web site
<http://www.druglibrary.org/schaer/hemp/medical/grinjama.htm> (January 10,
1998).
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~.. Roadblocks to Clinical Testing
Dr. Donald Abrams, an AIDS researcher, worked with the FDA to develop a
suitable protocol for a study of marijuana's eects on AIDS wasting syndrome.
The FDA approved ND No. 43,542 allowing Abrams to proceed. Abrams
encountered diculty, however, in obtaining the marijuana to perform the study.
The only legal access to Schedule I drugs is by importing it with the approval
of the DEA or obtaining it from a DEA registered domestic producer.'07 The
DEA refused to allow Dr. Abrams to import marijuana and the only registered
domestic producer in the United States, NIDA, refused to provide a supply.'08
Researchers in the United States were left with a Catch 22. The DEA refused
to reschedule marijuana until legitimate scientic research showed that it had
medical benets; however, the federal government was preventing researchers
from performing FDA approved research.
In 1996, marijuana advocates' assertions that politics, not science, was driv-
ing the government's resistance to marijuana and that the DEA had intention-
ally thwarted Dr. Abrams study were substantiated. After the DEA refused a
Freedom of Information Act request, Public Citizen sued the DEA and obtained
a letter written by the DEA to the FDA accusing it of approving an illegitimate
study and informing it that the DEA would not cooperate.'09 In the letter, the
DEA expressed its intention to prevent Dr. Abrams from importing marijuana
and to reject his request for registration to dispense a Schedule I drug unless
the FDA changed the study
t0721 C.F.R. 1301.18(a).
'08Lester Grinspoon, M.C. & James Bakalar, Marijuana. The AIDS Wastin2 Syndrome. and the U.S. Government,
New EDgiand Journal of Medicine, September 7, 1995, accessed at MAPS web
site <http://www.maps.org/mmj/nejm.htm.> (January 10, 1998).
'09Letter from Gene R. Haislip, Deputy Assistant Administrator, Drug En-
forcement
Administration to David A. Kessler, M.D., Commissioner, Food and Drug
Administration (June
8, 1994) accessed at The Marijuana Policy Project web site <http://www.mpp.org/deal.html>
(April 14, 1998).
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to t the DEA's criteria.0 The most distressing aspect of the letter is that it
indicated an eort by a law enforcement agency to force the agency responsible
for scientic evaluation of medicines in the United States to alter its scientic
procedures.
In the early 1990's, marijuana advocates were faced with a problem. In
1992, the government discontinued the compassionate ND program. Then in
1994, NORML lost its nal appeal to reschedule marijuana to Schedule II.
Finally, in 1995, NIDA and the DEA refused to allow an FDA approved study
on marijuana's ecacy to proceed. The advocates were left with conundrums
and Catch 22's, but without options.
Shortly thereafter, the movement tumed its attention away from the federal
avenues that had proven futile after twenty three years of eort, and directed its
eorts towards the states. This movement to the states was a reasonable and
natural progression of their eorts. Advocates felt that while federal politics
opposed medical marijuana, the people did not. They were right. In 1996 voters
in California and Arizona passed initiatives that would legalize marijuana, at
the state level, for medical purposes.
IV. Analysis of What Drafts of Future Medical Marijuana Initiatives
Can Learn from the Arizona and California Initiatives.
Now that medical marijuana activists have moved away from the traditional
routs of
change, they need to dene their ultimate goals. Marijuana advocates have
diverse ultimate goals; some see medical marijuana as the rst step in legalizing
either marijuana or all drugs, others care only about the issue of medical access
to marijuana, and others joined the movement because they disagree with gov-
ernment inuence in personal choices generally, and they see medical marijuana
prohibition as such interference. Activists who see medical marijuana legaliza-
tion as a step in a broader ultimate plan may prefer a dierent approach than
those
01d.
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focused strictly on obtaining medicine for the sick. For example, if mari-
juana is approved by the FDA and rescheduled, it still may not be distributed
without a prescription, and physicians and pharmacists must comply with strict
record keeping requirements.' Activists with strong libertarian leanings want
the government completely uninvolved with medical marijuana and see the is-
sue as one of personal privacy. These activists may disapprove of such stringent
controls of marijuana, especially if they seek to legalize marijuana completely
as the next step. They might prefer a system that hindered law enforcement
ocers by making it dicult for them to quickly distinguish medical marijuana
from black market recreational marijuana.
This paper does not attempt to divine medical marijuana activist's mo-
tivations and assumes that the ultimate goal is to achieve FDA approval of
marijuana and treatment by federal and state governments equivalent to any
other medical drug, unaected by politics.
A. ~
Notwithstanding the varied ultimate goals of medical marijuana initiative
drafters, pursuing state medical marijuana initiatives involves three more basic
goals or strategies that drafters must keep in mind: drafting an initiative that
the voters will pass, exerting pressure on the federal government to change its
policy, and creating a statute that works after the federal government does
change its policy. First, drafters must create an initiative that is politically
palatable to more than half of the voters so it will pass. An initiative that
allows anybody to get marijuana for any condition anytime without restriction
would certainly fail. Activists often feel
'21 C.F.R. 1306.05.
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that any concessions to placate their opponents constitutes capitulation or
selling out and they need to remain true to the cause regardless of the cost. The
failure of medical marijuana initiatives throughout the country, however, would
damage the movement and give opponents more credibility. In this case, it is not
better to have tried and failed than to never have tried at all. Therefore, drafters
must consider how the public will perceive the text and more importantly, in
what ways the text lends itself to negative spins by opponents.
Second, pressuring the federal government ows naturally from the rst goal.
A primary reason for passing an initiative is to pressure the federal government,
either to permit the research necessary to obtain FDA approval, or to back o
and acquiesce to the way states wish to regulate medical marijuana use. Such
policy changes would occur due to the political message state voters who pass
initiatives send to the federal government. They also come from the increased
responsibility the federal government must shoulder if certain types of drug
violations no longer violate state law. The federal government is simply not
equipped to investigate, arrest, and prosecute every dime bag dealer operating
in even one large state, let alone several.'12
Third, when the federal government does back o, either through a change of
policy or lack or resources, the state needs to have a workable system. When the
federal government changes its policy, it will not merely legalize marijuana, nor
will it acquiesce to the states forever. It will defer to the states until denitive
information on the risks and benets can be ascertained, whereupon it will
adjust its policy accordingly. During this time, the state law will
2The DEA rarely prosecutes possession for quantities anywhere near an
amount that would constitute personal possession. The average weight of mar-
ijuana for DEA conviction cases is over 300 pounds and the U.S. Attorney's
threshold policy for prosecution in Los Angeles and Orange County, California is
200 kilograms of marijuana or 200 plants. Hearings on the Arizona and California Medical Drug Use Initiatives Before the Senate Comm. on the Judiciarv,
(December 2,1996) (Statements of Tom Constantine, Administrator of the Drug
Enforcement Agency and Brad Gates, Sheri, Orange County, CA), available in
LEXIS Legis Library. Fednew File.
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govern medical marijuana use in the state. If the initiative is unworkable,
patients will suer. In many states, the legislatures cannot alter voter initiatives.
The only way to x the system would be to place a new initiative on the ballot,
which is not an attractive option. Therefore, drafters must balance the need to
draft a politically feasible initiative with the need to create a workable one.
Writing initiatives while balancing these multiple goals is a complex under-
taking. One not only needs to create a workable initiative, but one that voters
will approve. Some aspects of an initiative, however, may be desirable in devel-
oping a good statute, but are not politically acceptable. Other aspects are not
necessary to the eectiveness of the statute, but are politically popular and can
help an initiative gain needed votes. Other aspects may be politically damaging,
but are essential to a workable statute and must be included regardless of the
fodder it provides opponents.
The California, and to a lesser degree, Arizona initiatives provide an oppor-
tunity to examine what aspects of an initiative can create political liabilities,
which cause unforseen problems, and which are necessary to a properly func-
tioning medical marijuana statute. In this section, I will rst describe some
of the general criticisms directed at state initiatives. Then I will describe the
Arizona and California initiatives and what has occurred since they passed. Fi-
nally I will discuss the lessons medical marijuana advocates can glean from the
experiences associated with these initiatives.
B. Criticisms Leveled Against State Medical Marijuana Initiatives
Some criticisms opponents level at medical marijuana initiatives apply to all
initiatives. They argue that marijuana is not FDA approved, legalizing mari-
juana as a medicine sends the wrong message to children, and these initiatives
are attempts at backdoor legalization, evidenced
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by the fact that patients do not even need a doctor's prescription to use mar-
ijuana. These criticisms are really a product of the situation and drafters cannot
avoid them through changes to the texts. Nevertheless, the fundamental aw
in these criticisms suggest the possibility that opponents, many of whom hold
government positions, are willing to use disingenuous arguments and untruths
to defeat these initiatives.
1. Argument That Marijuana Is Not FDA Approved
Opponents argue that the FDA's purpose is to protect consumers from unsafe
drugs, and drugs therefore, should not be available without FDA approval.3
They argue that marijuana should be subject to the same approval process as
any other drug. General McCarey argued:
[A] llowing any potential medication to bypass [the FDA] process establishes
a loophole that threatens to undermine the imperative for rigorous science as
the basis for determining what constitutes good medicine."4
These opponents fail to note two problems with their argument. First, no
market incentive exists for anybody to obtain FDA approval for marijuana.5
Second, as discussed in Section HI, the federal government has thwarted at-
tempts by researchers to do the studies necessary for FDA approval. Given
the federal government's history of blocking studies on the potential medical
benets of marijuana, it is disingenuous for its representatives such as Orin
3James P. Fox, Michael J. Meyers, M.D., & Sharon Rose, Argument Against Proposition 215,
1996 California Election Pamphlet, reprinted in Cal. Att'y General's Oce,
Proposition
215: An Analysis (Dec. 20, 1996) Appendix I.
4Hearings On Medical Marijuana Referenda in America Before the Subcomm. on Crime of the House Comm. on the Judiciary,
105th Cong. (October 1, 1997) (Statement of General Barry R. McCarey, Di-
rector, Oce of National Drug Control Policy), ~ <http://www.whitehousedrugpolicy.gov/news/testimony/medical.html>
(April 23, 1998).
5 See Section HI, discussion on the lack of incentives to seek FDA approval
for marijuana
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Hatch and Barry McCarey to argue that marijuana should not be used for
medical purposes until the FDA approves it.6
2. Argument that legalizing marijuana for medical uses sends
the wrong message to children
The second argument opponents make against medical marijuana initiatives,
and the movement in general, is that approving marijuana for medical purposes
would send the wrong message to children.7 The opponents, however, fail to note
that both cocaine and opium are Schedule II drugs under the Controlled Sub-
stances Act. Both cocaine and opium have accepted medical uses in the United
States. Cocaine, for example, is used as a local anesthetic.8 Yet the opponents
do not seem to fear that cocaine's status as a medicine sends a message to chil-
dren that it is safe for recreational use. Opponents take a disingenuous position
when they argue that treating marijuana equivalent to cocaine and opium sends
the wrong message to children. If the marijuana activists had succeeded in cre-
ating parity in scheduling between marijuana and cocaine, they probably would
not have tumed to the state initiative movement because researchers would have
had less restricted access to marijuana to pursue FDA testing and physicians
could have prescribed it on an individual basis.
6Hearings on the Arizona and California Medical Drug Use Initiatives Before the Senate Comm. on
the Judiciary, (December 2, 1996), available in LEXIS Legis Library, Fednew
File.
7Hearings on the Arizona and California Medical Drug Use Initiatives Before the Senate
Comm. on the Judiciary, (December 2, 1996)(statement by Brad Gates,
Sheri, Orange County
California), available in LEXIS Legis Library, Fednew File; Hearings On Medical Marijuana
Referenda in America Before the Subcomm. on Crime of the House Comm. on the Judiciary,
105th Cong. (October 1, 1997) (Statement of General Barry R. McCarey,
Director, Oce of
National Drug Control Policy), accessed at
<http://www.whitehousedrugpolicy.gov/news/testimony/medical.html> (April
23, 1998).
8Stedman's Medical Dictionary 337 (2 1st ed. 1966).
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3. Patients do not even need a doctors prescription to use marijuana
The third general argument opponents make is that the initiatives are at-
tempts at backdoor legalization evidenced by the fact that patients do not even
need a doctor's prescription to use marijuana. ~ As discussed in Section IIC,
physicians who prescribe Schedule I drugs risk criminal prosecution and the loss
of their licenses to prescribe controlled substances. The initiatives seek to pro-
tect physicians by allowing them to merely recommend marijuana to patients.
The opponents understand this conundrum,'20 yet disingenuously seize it as an
opportunity to accuse the initiative drafters of attempting to surreptitiously
legalize marijuana.
C. Arizona
Arizona's Proposition 200 is a broad drug and crime bill that goes beyond
the medical marijuana issue and attempts to restructure the way Arizona deals
with drugs. It sought to redene the drug issue as a medical as opposed to
punishment minded one. Some of these issues go beyond the scope of this
paper. I will highlight them, but only go into detail on the issues surrounding
medical marijuana.
''James P. Fox, Michael J. Meyers, M.D., & Sharon Rose, Argument Against Proposition
215, 1996 California Election Pamphiet, reprinted in Cal. Att'y General's
Oce, Proposition
215: An Analysis (Dec. 20, 1996) Appendix I; Leon Worden, Marijuana Initiative is Bad
Medicine, The Signal, (Oct. 2, 1996), reprinted in
<http://www.scvleon.com/signa1/lwl00296.htm> (Feb. 5, 1997).
'20Cal. Att'y General's Oce, Proposition 215: An Analysis (Dec. 20, 1996)
at 5.
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1. Summary
a. General Provisions
Proposition 200 creates a nine member Parents Commission on Drug Ed-
ucation and Prevention appointed by the governor, consisting of parents, law
enforcement ocials, educators, and drug treatment experts.'2' This commis-
sion's mandate is to fund programs to increase and enhance parent involvement
and education on alcohol and drug problems.'2 The initiative provides for the
commission's funding through increased taxes on alcohol and tobacco.'23
Proposition 200 also requires people convicted of violent crimes while under
the inuence of a controlled substance to serve 100% of their sentences without
parole.'4 The initiative also provides that individuals in prison for personal
possession of drug charges be immediately eligible for parole.'25 As a condition
of their parole, they are required to participate in a drug treatment plan.'26
Furthermore, after the proposition takes eect, new individuals convicted of
personal possession charges will be given probation and required to participate
in a drug treatment program as a condition of such probation.'27 Individuals
convicted of simple
'21Arizona Proposition 200 x4(1).
'221d.
123pj xx4, 12.
l24~ x5.
125 ~ ~x8.
l26~ x9.
27J4 x10.
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possession charges for the third time would then be sentenced to prison under
the standard sentencing provisions.128
b. Provisions Relating to Marijuana
Proposition 200 allows seriously and terminally ill patients to possess con-
trolled substances, including those in Schedule I, when prescribed by a physician.'29
When prescribing schedule I drugs, doctors must comply with professional med-
ical standards and document that scientic research exists to support its use.'30
The doctor must also obtain a written second opinion by a second medical doctor
stating that the prescription is appropriate.'3' Finally, the doctor must obtain
written consent from the patient'32 Any failure to meet these requirements will
result in discipline by the board of medical examiners. As an additional safe-
guard, the initiative declares any information given in an eort to unlawfully
obtain a Schedule I drug will not be privileged doctor-patient communication.'34
Proposition 200 not only exempts patients from prosecution, but it creates
a distribution system by exempting participants in the legitimate drug distribu-
tion channel, from the doctor to the pharmacist and common carrier, from drug
prohibition laws when acting within guidelines of the statute.'35 Such guidelines
include a requirement that doctors and pharmacists act in good
18 ~J x 10(7).
l29~ x6(9).
130pj x7(l)-(2).
l3l~ x7(2).
132k x7(2).
133k x7(3).
134p~j x6(9)(3).
135pj x6.
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faith and in accordance with acceptable medical standards.'36 Allowing for
distribution as well as possession avoids the problems associated with the Cali-
fornia Proposition 215, which only exempts patients and primary caregivers from
prosecution. In that system, patients may possess marijuana, but they cannot
obtain the marijuana without causing another person to break the law.'37
2. Subsequent Developments
Proposition 200 does not oer observers a chance to study its implemen-
tation. Although it passed with 65.4%l38 of the vote, the Arizona legislature
eectively gutted the initiative. In Arizona, the legislature may amend initia-
tives passed by the voters as if they were any other statute. Taking advantage
of this loophole, the Arizona state legislature passed Ariz. H.B. 2518, which
does not allow the two sections of the initiative that relate to marijuana (xx 6,
7) to take
eect until Congress authorizes the medical use of marijuana or. .. the
federal food and drug administration authorizes the medical use of marijuana
and the drug enforcement administration reschedules marijuana to a schedule
other than schedule I.'~~ Arizonans for Drug Policy Reform, The group that
supported Proposition 200, has since renamed itself The People Have Spoken,
and is supporting a state initiative to overturn this legislation.'40
'36H x6(2).
'37Even patients who grow their own marijuana must obtain the seeds on
the black market.
'3tArizona Secretary of State web site, Unocial Election Results, <http://www.sosaz.comIresults/l996general/GEN5600.htm>
(January 14, 1998).
'39Ariz. H.B. 2518 (1997). See also Ariz. Stat. x13-3412.01.
'40National Organization for the Reform of Marijuana Laws (NORML),
Press Release. accessed at <http://www.pdxnorml.org/050897.txt> (April 18,
1998).
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D California
Because the Arizona legislature thwarted Proposition 200, California's Propo-
sition 215 is the rst and only medical marijuana initiative passed and imple-
mented. Therefore, it is the only tested guide for future medical marijuana
initiative drafters. Future drafters should avoid reinventing the wheel and learn
from the issues and problems generated both during the election and implemen-
tation process.
Proposition 215 is relatively simple and straightforward. It states the drafters'
intentions, and implements them in two sentences. Its simplicity is both a virtue
and a hindrance. It is easy to understand and did not confuse the voters with
technicalities. On the other hand, its lack of precision opened it to attack both
during the election and in its implementation. The California experience has
demonstrated the importance of technical precision in the text.
1. Summary
The California initiative entitled the Compassionate Use Act of 1996, added
Section 11362.5 to the California Health and Safety Code. The initiative has
two main sections. The rst section, 11362.5(b), expresses the intent of the
drafters. This expression of intent provides necessary denitions and guidance
for interpreting the statute. The second section, 11362.5(c)-(d), provides the
armative defenses to marijuana laws, or implements the intent expressed in
11362.5(b). The initiative also contains a severability clause protecting the
remainder of the initiative if a court declares a portion of it invalid.'4'
'41Cal. Proposition 215 x2.
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The initiative exempts patients and primary caregivers from marijuana culti-
vation and possession laws when they use marijuana for medical purposes based
upon the written or oral recommendation or approval of a physician.'42 It also
protects physicians from punishment or discipline for recommending marijuana
for medical purposes to patients.'3 These two exemptions summarize the heart
of the law: to protect patients, primary caregivers, and physicians who wish to
include marijuana in a patient's treatment. The initiative expressly withholds a
defense for conduct endangering others or for diverting marijuana to nonmedical
uses.'
The statute has two express denitions. First, a patient may use marijuana
for the following medical conditions: cancer, anorexia, AIDS, chronic pain, spas-
ticity, glaucoma, arthritis, migraine, or any other illness for which marijuana
provides relief.'45 Second, primary caregiver means the individual designated
by the [patient] who has consistently assumed responsibility for the housing,
health, or safety of that person.'~
2. Subsequent Developments
When proposition 215 passed in November 1996, it initially provoked strong,
negative responses from both federal and California government leaders. On
the other hand, passage of proposition 215 prompted numerous positive devel-
opments from the point of view of the medical
'42Cal. Proposition 215 x1; Cal. Health & Safety Code x 11362.5(d).
'43Cal. Proposition 125 x1; Cal. Health & Safety Code x11362.5(c)
'Cal. Proposition 125 x1; Cal. Health & Safety Code x11362.5(b)(2)
'45Cal. Proposition 125 x1; Cal. Health & Safety Code x1 1362.5(b)(A)
'Cal. Proposition 125 x1; Cal. Health & Safety Code x11362.5(e)
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marijuana movement. Examining these subsequent developments oers drafters
an opportunity
to observe how the initiative and its accompanying case law has developed.
a. Federal Response
Both California and Arizona passed initiatives that legalized marijuana for
medical uses, so the federal response was generally directed at both initiatives.
The initial federal response involved taking a bipartisan tough stance, harshly
criticizing the initiatives, and threatening to enforce federal law against physi-
cians and patients involved in medical marijuana.
Senator Orin Hatch convened a meeting of the Senate Judiciary Committee
in which, among others, General Barry McCarey, the Director of the Oce of
National Drug Control Policy, and Tom Constantine, the Administrator of the
DEA spoke.'47 The committee attempted to determine the ramications of the
initiative and develop a plan for handling the situation. Senator Hatch, General
McCarey, and Mr. Constantine all used the dearth of scientic studies and the
lack of FDA approval to justify their stance opposing the state initiatives.'48 In
his remarks, General McCarey said that the initiative was a hoax proposition
and called it a Cheech and Chong show.'49 Many speakers voiced fear, pointing
out unforeseeable consequences of the initiatives such as marijuana smoking
school bus drivers and people using marijuana for corns on their feet, with no
possibility for law enforcement agencies to stop such actions. ISO
'~ Hearings on the Arizona and California Medical Drug Use Initiatives Before the Senate Comm. on the Judiciary,
(December 2, 1996), available in LEXIS Legis Library, Fednew File.
'48Id
'49Id.
'501d.
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Both Mr. Constantine and Senator Hatch expressed concern as to whether
state and local law enforcement ocials had the authority to make an arrest
for violations of federal law in situations where neither the state or federal
government had no immediate plans to prosecute.'5' Mr. Constantine concluded
that the Controlled Substances Act did not provide such authority to local
agencies.1 They also expressed concern that federal agencies were not equipped
to handle the load of drug cases that could potentially be shifted from state to
federal responsibility.'53 Nevertheless, Mr. Constantine committed to prosecute
signicant drug trackers including physicians.
Four weeks later, the government was ready to address the issue with the
public. On December 30, 1996 General McCarey; Donna Shalala, Secretary of
Health and Human Services; and Attorney General Janet Reno issued a doc-
ument and briefed the public on how it intended to handle the situation)54
Attorney General Reno indicated that the government would consider prosecut-
ing or revoking the registration of any physician who rccommended marijuana
to patients.'55 She said that the government would not turn a blind eye to-
ward [its] responsibility to enforce federal law and preserve the integrity of the
medical and scientic process to determine if drugs have medical value before
allowing them to be used.'56 The written statement, on a stronger note, warned
physicians that the DEA would take action to
l5lI~
'Id.
'54News Conference With Drug Control Policy Director General Barry Mc-
Carey, Attorney General Janet Reno, and Donna Shalala, Secretary of Health
and Human Services, White House Brieng, December 30, 1996, available in
LEXIS Legis Library, Fednew File; 62 F.R. 6164.
'Id.
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revoke the registrations of physicians who prescribe or recommend mari-
juana, and the Department of Health and Human Services (HIHS) would ex-
clude them from participating in Medicare and Medicaid programs.' HHS and
the Department of Justice (DOJ) backed o of their position a bit and claried
their stance in a joint letter stating that it did not intend to institute a gag
rule and a physician could discuss the risks and benets of marijuana with a
patient, but 'physicians may not intentionally provide their patients with oral
or written statements in order to enable them to obtain controlled substances
in violation of federal law. Physicians who do so risk revocation of their DEA
prescription authority, criminal prosecution, and exclusion from participation
in the Medicare and Medicaid programs.58
In response to the Administration's hard line against physicians, a group
of California physicians and patients attempted to work out a compromise
with the federal government to prevent the abuses that the government feared.
They sought an agreement where the federal government would not prosecute a
physician who discusses or recommends medical marijuana in the physician's
best medical judgment and in the context of a bona de physician-patient
relationship.'59 McCarey and the Justice Department refused to the proposed
agreement, again asserting its ability to criminally prosecute physicians who
recommend marijuana to a patient. In response, the group led a class action
claiming that the government's threats to discipline physicians who recommend
marijuana to their patients caused a chilling of First Amendment
'~~62 F.R. 6164.
'58Conant v. McCarey, 172 F.R.D. 681, 688, 1997 U.S. Dist. LEXIS 8749
(U.S.D.C. Northern Dist. CA 1997).
'59Eric Brazil, Drug Czar Won't Budge: McCarey Rejects Doctors' Settle-
ment on MedicczI Pot, The San Francisco Examiner, February 9, 1997, C-2.
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speech rights'60 The government countered with the argument that recom-
mending marijuana crossed the line to assisting with a violation of the law.'6'
On April 30, 1997 the court issued a preliminary injunction against the gov-
ernment from imposing or threatening to impose criminal or civil sanctions on
physicians for actions that do not rise to the level of a criminal oense.'62 The
court recognized that what constitutes a criminal oense is not exactly clear,'63
but the case nonetheless gave physicians leverage in the dispute and stopped
the federal government from threatening physicians and patients.
The Justice Department then turned its attention to the buyers clubs, seek-
ing injunctions against six buyers clubs to force them to close.'64 It is inter-
esting to note that Justice did not target clients of the buyers clubs and chose
to le civil suits against the clubs and their operators instead of seeking crim-
inal charges. The Justice Department admitted that political considerations
inuenced their decision. The action against the buyers clubs indicates that
the federal government has moved away from its initial harsh, uncompromising
rhetoric.'65
'60Complaint, Conant v. McCarey, January 14, 1997. ~~~diI <http://www.lindesmith.org/mmjsuitIcomplnt.html>
(April 15, 1998).
Hearing Transcript of April 11, 1997 Plaintis' Motion for Preliminary In-
junction and Defendant's Motion to Dismiss, United States District Court for
the Northern District of California, accessed at <http://www.lindesmith.org/mmjsuitItranscrl.html>
(April 15, 1998).
'62Conant v. McCarey, 172 F.R.D. 681, 700, 1997 U.S. Dist. LEXIS 8749
(U.S.D.C. Northern Dist. CA 1997).
'63Id
'64Kate Rix, Feds Jump into Marijuana Club Prosecutions, The Recorder,
January 12, 1998. News 2.
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In addition to Senator Hatch and the Senate Judiciary Committee, both
houses of Congress have tackled the issue of the state initiatives. Although many
bills and resolutions die in committee, a House vote is scheduled for late April on
a Resolution declaring the House of Representatives's opposition to the medical
use of marijuana.'66 Other anti-medical marijuana bills have been introduced in
Congress, but remain in committee.'67 Judging from the text, they appear to
be knee jerk reactions with little chance of passing or being eective. One bill
has been introduced in Congress that would reschedule marijuana to Schedule
II, allow its use for medical purposes in states that permit such use, and require
the National Institute on Drug Abuse to provide marijuana for Investigative
New Drug Studies approved by the FDA.'68 This bill has ten co-sponsors and
was introduced to the Committee on Commerce on June 4, 1997 and to the
Subcommittee on Health and Environment on June 18, 1997. Otherwise it has
remained inactive.
Not all responses from the federal government, however, have been negative.
The federal government has also responded to the state initiatives in California
and Arizona with increased openness toward scientic testing of marijuana. In
January of 1997, General McCarey and the White House Oce of National
Drug Control Policy commissioned a study by the Institute of Medicine (IOM)
of the National Academy of Science (NAS) to conduct a comprehensive
'66H. Res. 372, 2nd Sess. 105th Cong. 1998.
'67H.R. 1265 (restricting certain benets for individuals convicted of state
oenses when the state does not prohibit marijuana for medical purposes); H.R.
1310 (requiring the Attorney General to revoke physicians' controlled substance
registration if they recommend an illegal substance); H.R. 3184 (reiterating
federal supremacy of Controlled Substances Act over state law).
'68H.R. 1782, 1st Sess. 105th Cong. 1987.
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review of the known health eects and potential medical use of smoked
marijuana.'69 Medical marijuana advocates were initially skeptical of such a
study, and felt that it was an attempt to give medical marijuana opponents a
token study to show that the government was addressing the issue, while avoid-
ing new studies of marijuana.'70 Some activists, however, have changed their
position, noting that the IOM group is looking beyond the existing, decades-
old research to the anecdotal evidence and is seeking public comment on the
issues.'7'
Additionally, in February 1997, the National Institutes of Health (NIH) held
a two day conference where it brought together an ad hoc group of experts
to study the medical marijuana issue.172 The group found that the existing
studies did not provide denitive answers; however, based on promising pre-
liminary evidence, it recommended new controlled studies.'73 It also recom-
mended that NIDA should supply marijuana to studies that meet U.S. regula-
tory standards.'74 Subsequently, in September 1997, NIDA not only agreed to
provide the marijuana
'69Statement by General Barry R. McCarey, Director, Oce of National
Drug Control Policy, Submitted for the Record to the House Judiciary, Commit-
tee, Subcommittee on Crime, Medical Marijuana Referenda in America, October
1, 1997, accessed at
<http //www whitehousedrugpolicy.gov/news/testimony/medical.html> (April
23, 1998).
170 Telephone interview with Paul Wolf, ACT UP (January 17, 1998).
'~' Telephone interview with Dave Fratello, Spokesperson, Americans For
medical Rights (April 2, 1998). ~ Teri Sforza, Pot useful or bad medicine? The
Orange County Register, December 14, 1997, A-i
'Workshop on the Medical Utility of Marijuana, Report to the Director, Na-
tional Institutes of Health, by the Ad Hoc Group of Experts (February 1997) ac-
cessed at <http://www.nih.gov/news/medmarijuana1MedicalMarijuana.htm> (April
5, 1998).
'731d.
'74Dened as FDA protocol approval and DEA controlled substances regis-
tration. Id. This denition is problematic because FDA approval of a protocol
does not guarantee the DEA will approve the controlled substance registration.
Letter to David A. Kessler, M.D., Commissioner. FDA, from Gene R. Haislip,
Deputy Assistant Administrator, DEA, June 8, 1994. (refusing to grant con-
trolled substance registration to researcher with approved ND, citing insucient
FDA assurance of scientic integrity).
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for Dr. Abrams's study on AIDS wasting, but it gave Dr. Abrams a $978,000
grant for the study.'75 The two-year study will be the rst FDA-approved study
of the use of smoked marijuana in a patient population in about fteen years.'76
Ironically, had the federal government taken these steps toward allowing research
two years earlier, it may have never had to deal with the problems spawned by
the state initiative movements.
b. State Response
On the state level, the response by leaders was critical, albeit a bit unsteady.
Attorney General Dan Lungren called Proposition 215's passage a disaster.' His
oce expressed concern at the legal anarchy the initiative created, but admitted
no plans to challenge the new law, noting that it would not have standing.'78
Close to a year after the initiative passed, Lungren softened his stance on the
idea of clinical testing. While he maintained that Proposition 215 was a dumb
idea, he expressed support for a state Senate bill that would provide for testing
of marijuana's medical value and agreed to provide the marijuana if the federal
government refused.'79
'75Multidisciplinary Association For Psychedelic Studies, Medical Marijuana
Research in the 90's : The struggle to begin a medical marijuana research project
(updated April 1998), accessed al <http://www.maps.org/mmj/index.htm1>
(April 15, 1998). ~ Section IIIC discussing Dr. Abrams's study.
176 Multidisciplinary Association For Psychedelic Studies, Medical Mari-
juana Research in the
90's : The struggle to begin a medical marijuana research project (updated
April 1998), accessed a! <http://www.maps.org/mmj/index.html> (April 15,
1998).
'Jon Mathews, Voters favor medical marijuana, San Francisco Bee, Novem-
ber 6, 1996, AlS.
'78Eric Brazil, Medicinal Marijuana Vote Stymies Lungren, The San Fran-
cisco Examiner, November 7, 1996, A-8.
'79Robert B. Gunnison, Lungren Backs Medical Pot Study, The San Fran-
cisco Chronicle, August27, 1997, A18.
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Lungren has also actively opposed the buyers clubs. The buyers club concept
and their involvement in distributing medical marijuana predates Proposition
215. After Proposition 215, more buyers clubs began forming throughout the
state. The state and federal governments, however, did not turn the expected
blind eye and are seeking to close them. Because Proposition 215 does not con-
tain a provision for distribution, the buyers clubs turned to the primary caregiver
clause for protection. Purporting to t a buyers club into the primary caregiver
denition of an individual designated by the [patient] who has consistently as-
sumed responsibility for the housing, health, or safety of [the patient].'80 is a
stretch, but it is the only avenue. Denis Peron, the operator of the Cannabis
Cultivators Club, the largest and most famous club in California serving over
9,000 clients,'8' asserted that he was a primary caregiver to his clients after the
California Attorney General's oce sued to enjoin his operation.'82 A California
appeals court
rejected Peron's argument and ruled that buyer's clubs do not t the criteria
of a primary
183
caregiver.
The court also ruled that Proposition 215 only protects patients and primary
care givers from prosecution for marijuana possession and cultivation. It does
not provide any defense for people who sell or distribute it outside of a patient-
primary caregiver relationship. Thus.. . one who sells, furnishes, or gives away
marijuana to a patient or qualied primary caregiver...
'80Cal. Health and Safety Code x11362.5(e).
'81Mary Curtius and Maria L. La Ganga, Judge Orders Closure of Cannabis Club,
Los Angeles Times, April 16, 1998, A 3.
'82The Attorney General's Oce brought suit prior to Proposition 215, and
Peron asserted the defense after its passage.
'83Lungren v. Peron, 59 Cal. App. 4th 1383, 1390, 70 Cal. Rptr. 2d 20
(1997).
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violates the law.'84 The court noted that the drafters expressly avoided pro-
viding a defense for sale and distribution, even though they could have easily
done so.'85 Although it recognized the dilemma of patients who, while immune
from prosecution themselves, put those from whom they purchased marijuana
at risk, the court refused to interpret the statute in a manner that would con-
tradict the way it was presented to the electorate.'86 On April 16, 1998 a state
court issued a permanent injunction against Peron, citing illegal sales as the
primary reason for the injunction.'87 The criminal trial is still pending.'88
In a twist of events that shows the strong division among government au-
thorities in California on the medical marijuana issue, the San Francisco County
Sheri refused to close the club as ordered by the judge. Although Lungren an-
nounced that he would act to enforce the injunction if the Sheri refused, he
found himself on weak footing because prosecutions for violating the injunction
fall under the jurisdiction of the San Francisco District Attorney, who also sup-
ports the buyers clubs and appeared unlikely to prosecute.'89 Ultimately, the
sheri closed the buyers club, which reopened the next day under a new name,
and Lungren is now in litigation to close the new buyers club.
I84j~~ at 1395. The court did acknowledge that a patient could reimburse
a caregiver for expenses related to cultivation, or preclude a caregiver from
charging the patient for caregiver services. Id. at 1399-1400.
'85Lungren v. Peron, 59 Cal. App. 4th at 1394.
'861d at 1394-5.
'Mary Curtius and Maria L. La Ganga, Judge Orders Closure of Cannabis Club,
Los Angeles Times, April 16, 1998, A 3.
'88California Department of Justice, Proposition 215 Update #10, December
8, 1997; People v. Dennis Peron, Beth Moore, et al. (Alameda County).
'89William Claiborne, San Francisco's Political Potboiler in Fight Over Marijuana as Medicine. Sheri
Backs Growers, Washington Post, April 17, 1998, A3.
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Notwithstanding Lungren's battle with Peron, Lungren appears to have
mildly softened his stance on buyers clubs. After his oce obtained the injunc-
tion against Peron's club, Lungren declined to discuss possible actions against
other buyers clubs in the state, possibly indicating that he recognizes that law
enforcement against buyers clubs will not resolve the medical marijuana issue.
Lungren said, rather than continuing the debate about cannabis buyers clubs,
let's tum our focus to a question that is still undetermined{whether marijuana
has any medicinal
1%
Positive developments
Not all government responses to Proposition 215 have been negative, espe-
cially at the local level. Many community leaders have voiced their support
for the initiative and many communities have made eorts to accommodate pa-
tients. In response to a suit by the federal government seeking to shut down the
buyers clubs in California, on March 18, 1998 mayors from four cities, includ-
ing San Francisco Mayor Willie Brown, sent letters to the White House asking
the Clinton Administration to let local communities handle the buyers clubs.'9'
They do not want to see their residents compelled to seek out their marijuana
in back alleys and street corners. 92 In a further act of deance, San Francisco
City District Attorney threatened to use city workers to distribute marijuana if
the federal government shut down the local buyers clubs.' Other
'~Mary Curtius and Maria L. La Ganga, Judge Orders Closure of Cannabis Club,
Los Angeles Times, April 16, 1998, Part A; Page 3.
'91Russell Sabin, 4 Mayors Call on Clinton to Stop Pot Club Prosecutions,
The San
Francisco Chronicle, March 19, 1998, A 15. The following mayors wrote
letters to President
Clinton: San Francisco Mayor Willie Brown, Oakland Mayor Elihu
Harris, West Hollywood
Mayor Steve Martin, and Santa Cruz Mayor Celia Scott.
'921d.
'John Lyons, S.F. Set to Defend Medical Pot Clubs, Sacramento Bee, March
22, 1998, A8.
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communities have responded to proposition 215 by instituting guidelines to
regulate medical marijuana in their communities. The City Council of San Jose,
California unanimously passed an ordinance regulating marijuana dispensaries
within the city.'94
Local Law enforcement ocials have also shown their willingness to accom-
modate Proposition 215. In San Francisco, the Sheri announced that he would
accommodate prisoners who needed marijuana for medical purposes.'95 In Ar-
cata, California, the Chief of Police has issued forty watermarked cards with the
patient's photograph, the city's seal, and his signature to those for whom physi-
cians have recommended marijuana. 1% His attitude is The spirit of the law
here is you have a defense, let's assert it on the corner instead of in court. It's
a 10-second contact where before it would take hours.'97 This registration sys-
tem has even received guarded praise from John Gordnier, the Deputy Attorney
General prosecuting the civil case against Denis Peron's buyers club.'98 Perhaps
the most surprising show of cooperation occurred in Mountain View, California
where police arrested an AIDS patient for cultivating marijuana. The district
attorney's oce told the police it would not prosecute anyone who cultivated
marijuana solely for medical purposes and that they should give his marijuana
and cultivating equipment back, which they did.'~
'94City of San Jose, California Ordinance No. 25280, March 25, 1997.
'95Alex Roth, S.F. Sheri Will Permit Medical use of Marijuana by County-jail Inmates,
Los Angeles Daily Journal, April 28, 1997, 3.
'96Kate Rix, Grass Roots Take Hold of Prop 215, The Recorder, March 11,1998,1.
'Id.
'Id.
'9Emelyn Cruzlat, Cops Give Back Aids Patient's Pot Plants, The San Fran-
cisco Examiner. March 2, 1997,A I.
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E. Lessons learned form the California and Arizona Initiatives.
In this section I will discuss what drafters of medical marijuana initiatives
can learn from the California and Arizona experiences. In these discussions I
will also allude to currently active initiatives, although I will not discuss them
in detail until Section V. I will rst address how certain aspects of the initia-
tives created political liabilities, and which of those liabilities can be avoided
and which cannot depending on if they are necessary for a properly functioning
initiative. Second, I will discuss which aspects of the initiative hindered the
goal of creating a workable statute. Some of these problematic aspects are not
necessarily attributable to the presence of problematic text or the absence of
necessary text, but can also result from judicial decisions and state agency inter-
pretations. A properly functioning statute must withstand or prevent adverse
judicial and administrative interpretations. Finally I will discuss the aspects of
the initiatives that have not yet proven problematic, but still pose hazards to a
properly functioning statute.
1. Political issues
a. Political Issues Resulting From Necessarv Provision in the Initiative
Although not requiring patients to obtain prescriptions from their physicians
for marijuana, subjects an initiative to harsh criticism, protecting physicians
from prosecution and discipline is imperative to a workable statute. Therefore,
no initiative should require patients to obtain a prescription for marijuana. The
term recommend is the term of choice; however, Conant v. McCarey has not
yet resolved the issue of whether a physician recommending marijuana to a
patient is protected by the First Amendment. Although the physicians won the
preliminary injunction, the issue must still be resolved at trail. The Florida
drafters have tried an interesting approach to avoid the uncertainty of the term
recommend. By merely requiring physicians to
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certify that marijuana is medically appropriate and the patient may benet
from its use. This
language merely requires the physician to express an opinion, something
clearly covered by the First Amendment. Regardless of whether drafters choose
recommend, certify, or some other term, they cannot require a prescription,
regardless of the political liability such an omission can create.
k1 Avoidable Political Issues
One of the most politically damaging criticisms of Proposition 215, that it
permits unfettered use by minors, was avoidable. The initiative did not ad-
dress the issue of minors, mostly due to its simplicity. Nevertheless, it provided
opponents with a persuasive argument, illustrated by such headlines as Even
Children Could Smoke Pot Legally!20 ~' The California Attorney General inter-
prets the initiative to allow children to grow and use marijuana, and wams that
minors with primary caregivers who are not their parents could conceivably use
marijuana legally without parental knowledge or consent. His oce has taken a
position, however, that doctors would be on weak footing if they recommended
marijuana to minors. He notes that
numerous studies indicate marijuana is dangerous to youths and claims that
no anecdotal studies
201
He reco
that indicate medical benets of marijuana in children exist. mmends
using child
200 James P. Fox, Michael J. Meyers, M.D., & Sharon Rose, Argument
Against Proposition
215, 1996 California Election Pamphlet, reprinted in Cal. Att'y General's
Oce, Proposition
215: An Analysis (Dec. 20, 1996) Appendix I.
201Cal. Att'y General's Oce, Proposition 215: An Analysis (Dec. 20,
1996) at 9; Cal. Att'y Gen Peace Ocer Guide: Compassionate Use Act of
1996, 3. Although the Attorney generaUs oce claims that no anecdotal stud-
ies indicating medical benets of marijuana in children exist, and has made this
claim to police departments throughout the state in its Peace Ocer Guide, this
information is inaccurate. In his decision stemming from the public hearing on
NORMIL's rescheduling, Judge Young found several anecdotal claims that mar-
ijuana helped children and teenagers with the side-eects of chemotherapy to be
persuasive. In the Matter of Marijuana Rescheduling Petition, Opinion and Rec-
ommended Ruling, Findings of Fact, Conclusions of Law and Decision of Admin-
istrative Law Judge Francis L. Young, September 6, 1988, No. 86-22, pages 20-
23, accessed at <http://mojo.calyx.notkolsenJMIEDICAL/yoUNG/yo~g I html>
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welfare laws to intervene and warns of possible police department liability
for not intervening. when a minor is involved202
Opponents of the initiative conveniently interpret it in two ways. During
the election, they interpreted it broadly in an eort to scare voters with tales
of children supplying children. After the election, they construed it narrowly
to prevent any access to children. The initiative's silence on the issue was
more harmful than any reasonable approach. If initiate drafters do not want
to provide access to minors, then they should explicitly exclude them, thereby
avoiding harsh criticism for allowing minors. If they do want to provide access
to minors, they should include them and provide guidelines to avoid minors
using marijuana without their parents' consent. Whether a drafter wishes to
include minors or not, the issue is too explosive to ignore and all initiatives
should contain a clause addressing the issue.
c. Judgement calls
I. Illnesses that qualify for treatment with marijuana
Some aspects of initiatives that create political liability are avoidable, while
others are unavoidable. In other cases, drafters must make a judgment call after
weighing the political liability against the desirability of the provision. First,
drafters must decide whether they want to allow patients to use marijuana for
any illness and trust physicians to recommend it prudently, or restrict the list
of eligible conditions to an enumerated list. Proposition 215 has a clause at
the end of its list of serious illnesses that says, or any other illness for which
marijuana provides relief. This clause garnered substantial criticism from oppo-
nents. They claimed that this clause opened the door to any disease including
stress, headaches, upset stomach, insomnia, a sti
(January 10, 1998).
202Cal. Att'y Gen Peace Ocer Guide: Compassionate Use Act of 1996, 3
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neck. .. or just about anything.203 General McCarey cited a medical adviser
to Proposition 215 who listed writer's cramp and corns on toes as conditions for
which marijuana may provide relief.204 The statute leaves a lot to the discretion
of doctors. While such discretion is common with most other drugs, it poses a
political problem in this case.
Some initiative drafters may not want to limit the scope of what marijuana
can be used to treat. One cannot contemplate what new diseases may occur, for
which marijuana may prove useful. Had the California initiative been drafted
in the 1970's, it would not have included AIDS, a relatively new disease. Fur-
thermore, with the increased interest in medical uses of marijuana, new uses
may be discovered, requiring a new initiative if the original did not include a
savings clause. On the other hand, drafters may feel that marijuana's use should
be limited until it can be tested in clinical trials. For these drafters, the state
initiatives are primarily focused on pressuring the federal government to change
its policy. Consequently, limiting marijuana to those illnesses that marijuana is
currently reputed to aect would be acceptable. Regardless of which philosophy
drafters subscribe to, they need to balance the political risks associated with
an open denition of illness against the benets of including all individuals who
may benet from marijuana.
ii. Legalizing other Schedule I drugs as well
The second issue requiring drafters to make judgement calls is whether the
initiatives should legalize drugs other than marijuana for medical use. Arizona's
Proposition 200 legalizes all schedule I drugs for medical purposes. The drafters
of the initiative nevertheless view it as a
203James P. Fox, Michael J. Meyers, M.D., & Sharon Rose, Argument Against Proposition
215 1996 California Election Pamphlet, reprinted in Cal. Att'y General's
Oce, Proposition
215: An Analysis (Dec. 20, 1996) Appendix I
204Hearings on the Arizona and California Medical Drug Use Initiatives Before the Senate Comm. on the Judiciary,
(December 2, 1996).
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medical marijuana initiative because the initiative requires physicians to
document existing scientic research to support a drug's use, and the drafters
indicate that they are aware of no other schedule I drug for which scientic
research exists to support its use. They contend that they chose to include all
Schedule I drugs so that if scientic research established the validity of the use of
a substance for medical purposes, they would not have to return to the public
with another initiative.205 Although this reasoning makes sense, drafting an
initiative that potentially legalizes drugs such as PCP and heroin is politically
dangerous. Many attribute the failure of a 1997 Washington State initiative to
its inclusion of all Schedule I drugs instead ofjust marijuana. Although including
other drugs besides marijuana is a judgement call of the drafters, in most cases,
it would be unwise.
2. Problems That Have Arisen in the Wake of Propositions 200 and
215 In addition to the political issues that relate to whether voters will pass an
initiative,
drafters of initiatives need to be aware of a number of issues that have proven
problematic in terms of deriving a workable system from an initiative.
20S$~ Hearings on the Arizona and California Medical Drug Use Initiatives Before the Senate
Comm. on the Judiciary, (December 2, 1996) (Comments by Marvin Cohen,
treasurer of Arizonans for Drug Policy Reform).
While I am not sure which side of the debate would consider the following
information more advantageous to their arguments, evidence exists to support
claims that MDMA, commonly known as Ecstasy, has medical value in psy-
chotherapeutic treatment. In 1986, an administrative law judge determined
that MIDMA had an accepted medical use for treatment in the United States
and was safe to use under medical supervision. S.~ Grinspoon, M.D., v. DEA,
828 F.2d 881, 884 (1st Cir. 1987). Furthermore, signicant research is being
pursued to ascertain the safety and ecacy of MDMA. The Multidisciplinary
Association for Psychedelic Studies (MAPS) currently facilitates such research
and has opened a Drug Master File for MDMA with the FDA. The opponents
of Proposition 215 could point to these facts to show that the initiative would
apply to more than marijuana. On the other hand, one could point to the battle
marijuana advocates have been forced to wage, and argue that the Proposition
200 drafters are right not to want to have to go through such eorts each time
a Schedule I drug shows medical promise.
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a. No distribution mechanism
The California initiative does not address the issue of access to marijuana,
except to allow the patient and primary caregiver to grow the marijuana for
personal uses.206 The initiative drafters included a clause that encouraged the
federal and state governments to implement a plan to provide for the safe and
aordable distribution of marijuana.,'207 They did not, however, provide a mech-
anism for distribution.
The main reason the drafters did not include a distribution system was to
make the initiative more politically attractive.208 They felt that the government
would recognize the conundrum and turn a blind eye to buyers clubs.209 They
also wanted to avoid conicts with federal law.210 As the initiative was written,
there is no positive conict with federal law. The government has no ability to
attack the initiative on preemption grounds and must attack it collaterally, by
closing buyers clubs, sanctioning physicians, or arresting patients under federal
law. Regardless of the reasons, the strategy backred in Califorma.
With both the federal and California state government prosecuting buyers
clubs, and the case law determination that distributors are not protected, Cal-
ifornia patients are put in a precarious situation. They can either grow their
own marijuana, which would entail obtaining seeds on the black market; not
use marijuana at all, which would defeat the purpose of allowing medical use;
or obtain marijuana on the black market, which would place patients at risk as
they
206Cal. Proposition 215 x1; Cal. Health and Safety Code x11362.5(d).
207Cal. Proposition 215 x1; Cal. Health and Safety Code x1 1362.5(b)(l)(C).
208Telephone Interview with Ed Rosenthal (April 22, 1998).
2091d.
'0E mail from Dave Fratello, Spokesperson, Americans for Medical Rights
to Don Christen. Maine Vocals (on le with author).
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associated with a criminal element. Probably the biggest problem with cre-
ating an initiative that lacks a distribution system is that even if the federal
government changes its policy towards buyers clubs, they will still violate state
law. Theoretically, the federal government could either explicitly or implicitly
permit buyers clubs to operate, and the California Attorney General could still
shut them down and thwart distribution.
To protect patients and create a workable distribution system, drafters have
three options:
exempt marijuana sales along with possession and cultivation, distribute the
marijuana themselves, or license marijuana distributors.21' All three approaches
have drawbacks. It is important to note that no system would protect distrib-
utors from federal laws against marijuana and that federal agencies are more
likely to prosecute a marijuana distributor than a patient.
The rst option to rescind state laws as they apply to the sale or distribution
of medical marijuana avoids positive conict with federal law and would permit
buyers clubs to operate without fear of state law enforcement. It is not a
state's refusal to impose some law that typically triggers preemption concerns,
but a state's positive regulation of some matter in a manner inconsistent with
federal regulation.212 On the other hand, legalizing marijuana sales without any
government control or oversight creates political liabilities. Opponents would
focus on how the initiative legalizes drug dealing and protects hardened drug
dealers from police intrusion into their deals.. For voters, protecting patients is
more palatable than drug dealers.
The second approach requiring the state to set up a distribution program
would give the state total control over marijuana distribution and avoids turning
the system over to drug dealers. A state agency would be able to limit diversion
of marijuana tor recreational users. Police
21 idea was developed by Colorado Citizens for Compassionate Cannabis.
212U.S. v. Leal, 75 F.3d 219, 227 (6th Cir. 1996).
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ocers would know for a certainty that observed street deals were illegal
because all legitimate sales of marijuana would occur through the state agency.
This program is ideal, except that such a provision would require states to
directly violate federal law, subjecting the initiative to preemption. Such a
provision is probably preempted under the Supremacy Clause of the United
States Constitution: ~ In essence, a state distribution system equates to no
distribution system until the federal government agrees to turn a blind eye.214
The third approach, licensing marijuana distributors, is somewhat of a com-
promise between the two other options. Under this approach, the state can
maintain some level of control over the sale or distribution of marijuana for
medical purpose, but it does not have to directly violate federal law. The pri-
mary danger of this option is that the federal government would demand the list
of licensees from the state, and then prosecute them. While this danger is real,
people involved in distributing marijuana are aware of the risks they take. The
buyers clubs are not trying to keep themselves hidden from the DEA. This third
option also raises a question of federal preemption, but one can make a strong
argument that a state licensing requirement does not conict with federal law
prohibiting the activity for which the license must be obtained.
213U. S. Const. art. VI.
214Lawyers in California are currently considering whether 21 U.S.C.A. 885(d)
may provide a way for state and local governments to distribute marijuana. Sec-
tion 885(d) exempts state and local ocials from liability when they are engaged
in the enforcement of laws or ordinances relating to controlled substances. One
could argue that distributing marijuana in compliance with a state law or local
ordinance would be exempt from the CSA under this statute. Telephone Inter-
view with Je W. Jones, Co-Founder and Executive Director, Oaldand Cannabis
Buyers' Cooperative (April 23, 1998). On the other hand, the underlying law
or ordinance can be preempted. This clause has virtually no case law and the
intricacies of an issue of rst impression such as this are beyond the scope of
this paper.
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The Supreme Court has found that a federal statute pre-empts state law if
the federal statute indicates congressional intent to exclusively occupy a eld
of law or if the state law is in actual conict with the federal law.2'5 Congress
declared in 21 U.S.C.A. x903 that it did not intend to exclusively occupy the
eld of controlled substances and that the federal act should only pre-exempt a
state law if a positive conict exists so that the two cannot consistently stand
together.216 The dicult question is whether a state statute that allows the state
to grant licenses for activities that conict with the CSA positively conicts with
the federal law so that they cannot consistently stand together. In other words,
does a licensing requirement move from a refusal to impose a law to positive
regulation that prevents the full implementation of the CSA? As long as the
state acknowledges that people who distribute marijuana are still subject to
federal law, a licensing program would not hinder the CSA.
Although the courts have not addressed the issue directly, one can analo-
gize a state licensing program for behavior prohibited by federal law to a state
tax on an activity that violates federal law. For example, as long as a state
avoids double jeopardy issues, it may tax the possession of marijuana.217 Such
a tax would constitute state regulation of an activity that violates federal law.
Furthermore, the Supreme Court has recognized that, in some circumstances,
granting a license must be regarded as a form of imposing a tax, and grants no
rights nor implies any protection except that the licensee will not be subject to
penalties for not having a license.218 Finally, if states seek to license medical
marijuana distributors and do not
215Freightlinerv. Myrick, 115 S.Ct. 1483, 1487, 514 U.S. 280 (1995).
21621 U.S.C.A. x903.
217Department of Revenue of Montana v. Kurth Ranch, 114 S.Ct. 1937,
1945, 511 U.S. 767 (1994).
218License Tax Cases, 72 U.S. 462, 471, 18 L.Ed. 497 (1866).
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attempt to regulate them in any way that would require them to violate
federal law, the state regulation should be viewed merely as a regulation less
stringent in nature than federal law. States have the authority to co-regulate
the eld of controlled substances, but are not required to institute regulation as
strict as federal law.219 Although the law relating to state licensing of marijuana
distributors is not completely clear, drafters should feel relatively comfortable
including a licensing program as a way of providing a distribution system while
maintaining a level of oversight and control.
k1 The Initiative Does Not Dene Usable Marijuana or Personal Use.
The California initiative fails to dene the terms usable marijuana and per-
sonal use. It states that a patient who possesses or cultivates marijuana for
p~~na1 medical purposes is exempt from marijuana laws, but it does not de-
ne what personal use means. The California courts have indicated that in the
context of cultivation, the amount constituting personal use varies depending
on the circumstances, and personal use is determined by intent, not amount.~0
Such a determination is not one that a district attorney or police ocer can
make. It is a question of fact that the courts must decide.22' While California
law is equipped to handle Proposition 215's jack of precision, initiative drafters
should not rely on state law or state law enforcement ocials to dene accept-
able levels of marijuana.
For example, notwithstanding the case law, the California Attorney General
has taken the position that more than two plants, 60 cigarettes, or 28.5 grams
(one ounce) of marijuana may exceed that which is necessary for personal use,
and individuals caught with more than that
21921 U.S.C.A. x903.
205ee People v. Williamson, 137 Cal. App. 3d 419, 422, 187 Cal. Rptr. 107
(1982).
2215ee Id. See also People v. Brackett, 25 Cal. App. 4th 488, 497-98, 30
Cal. Rptr. 2d 557 (1994) (explaining State v. Williamson).
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amount may not be covered by the Compassionate Use Act.222 While the At-
torney General recognizes that possession of amounts in excess of his guidelines
may be legal, in his Peace Ocer Guide, intended to guide California police in
dealing with the Compassionate Use Act, he notes in bold type that quantities
over 28.5 grams or two plants may violate the Act.223 Police not familiar with
the nuances of California common law will probably not ponder the use of the
word may when deciding whether to arrest a patient. This situation illustrates
that state ocials given signicant discretion could gut an initiative by not
allowing patients to have enough marijuana to treat their conditions.
Before an initiative drafter decides how much marijuana cultivation and
possession to allow, one needs to look at patient needs and how much they
use, as well as how many plants it takes to produce that supply. Patient need
depends on a host of variables such as weight, tolerance, type of illness, quality
and potency of marijuana, and method of use (eaten, smoked, tincture, etc.).
This paper does not purport to perform an in-depth analysis of patient needs.
It only seeks to give rough estimates to show what a reasonable amount of
marijuana would be.
The federal government currently distributes eight grams per day to the
remaining eight patients in the compassionate ND program, although the Oak-
land Cannabis Buyers' Cooperative notes that the government marijuana is
poor quality.224 The Oakland buyers club oers two to ve grams as a reason-
able average for its patients. Taking a daily average three grams less than what
the government supplies its patients, if a patient uses ve grams of marijuana
per day, that
224 Telephone Interview with Je W. Jones, Co-Founder and Executive Di-
rector, Oakland Cannabis Buyers' Cooperative (April 23, 1998).
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would amount to 1,825 grams (64 ounces), or four pounds, per year. There-
fore, even a weeks supply would exceed the California Attorney General's de-
nition of personal use.
The following discussion outlines amounts and yields of marijuana plants
indoor and outdoor)25 Marijuana experts note that production is generally not
measured in yield per plant, but per square foot cultivated. Furthermore, yield
depends greatly on size of the plant. This discussion, therefore, should not
be considered anything more than a rough guide intended to allow a reader to
conceptualize the scale on which patients must cultivate to satisfy their personal
use needs.
Patients generally use only the owers or buds of the female plant. Except
for baking into food, such as brownies, they rarely use the leaves. Therefore,
male plants are of little use to patients. If leaves were included, the per plant
yield calculations would change dramatically. An indoor grow can produce
four harvests per year, or has a three month growing cycle, while an outdoor
grow results in one harvest per year. Plants are generally discarded after a
single harvest. Indoors, an average plant might yield one-half ounce of usable
marijuana. Therefore, to grow enough marijuana to last the patient through
the next growing cycle, a patient would need thirty-two plants and a harvest of
one pound. Outdoors, a patient needs to obtain an entire year's supply from
one grow. A reasonable yield for an outdoor plant is three ounces. Therefore, to
grow the necessary four pounds that would constitute an average year supply,
a patient would need twenty-two plants.
225The information regarding marijuana cultivation was provided by Je
W. Jones, Cofounder and Executive Director of the Oaldand Cannabis Buyers'
Cooperative and Ed Rosenthal. Both felt that the number of variables involved
in cultivating marijuana prevented an accurace estimate of per plant yields.
Mr. Jones did provide some rough numbers from which I could calculate. Mr.
Rosenthal maintains that per plant yields cannot be accurately estimated.
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An average patient, using less than the government supplies the compassion-
ate ND participants with could reasonably possess thirty-two owering plants
and a number of nonowering plants and seedings right before a harvest, or four
pounds of useable marijuana right after a harvest. These gures do not take
into account poor farming techniques, loss of crop, above average medical need,
male plants, or a host of other variables.
The problem these numbers create for initiative drafters is that even reason-
able limits on possession such as 100 plants, 40 of which may be owering, or ve
pounds of usable marijuana would probably shock voters and give opponents
additional fodder to claim surreptitious legalization. Taking voters through the
steps I just outlined is impossible in an election campaign that functions on ten
second sound bites and emotion. Therefore, attempting to enumerate specic
limits on possession and cultivation is unwise. Limits that accurately t patient
needs would be politically harmful while limits that may appear reasonable to
voters would continue to place patients in jeopardy of state law. Avoiding the
issue, however, places the initiative in danger of interpretations such as the Cali-
fornia Attorney General's. Initiative drafters face a conundrum. As discussed in
Section V, both AMR's Washington D.C. initiative and ACT UP's Washington
D.C. initiative limit the allowable amount to that which is necessary under the
circumstances, while AMIR's initiative still imposes a two month limit. This
approach may prove to be the best course of action. Personal use is a loaded
term in the area of controlled substances because it is used, often arbitrarily,
to determine harshness of criminal sentences. Moving to a medically necessary,
or similar, denition would avoid the baggage accompanying the term personal
use and still maintain the exibility patients need.
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c. The Initiative Restricts Coverage to California Residents
The initiative states that it is intended to ensure that seriously ill Californians
have the right to obtain and use marijuana for medical p~oses... . (em-
phasis added). The California Attorney General's Oce has interpreted this
clause to mean that only California residents are protected by this law. In his
Peace Ocer Guide, the Attorney General advised law enforcement authorities
that the initiative does not cover out-of-state residents, temporary visitors, or
illegal aliens.226
The Attorney General's attempt to limit the application of the Compassion-
ate Use Act of 1996 to California residents is problematic in two ways. First,
the term resident is dicult to dene. The California Supreme Court noted:
Residence, as used in the law, is a most elusive
~~227
Its me
and indenite term. aning depends upon the context and purpose of
the statute in
which it is used.228 How will college students be treated? How will patients
who come from other states to California hospitals for extended, yet hopefully
temporary treatment be aected? The law is unclear. Furthermore, police o-
cers will have a dicult time determining in a eld encounter whether someone
is a Californian for the purposes of the Compassionate Use Act of 1996. To
compound the problem, a person can be a resident of more than one state and
have several 'residences' for dierent purposes.229 On the other hand, using the
term domicile does not oer a solution because domicile requires an intent to
remain.230 Therefore, under a
226Cal. Att'y Gen Peace Ocer Guide: Compassionate Use Act of 1996, 1.
227Smith v. Smith, 45 Cal. 2d 235, 239, 288 P. 2d 497, 499 (quoting Briggs
v. Superior Court,
81 Cal. App. 2d 240, 245).
228Myers v. Carter, 3 Cal. Rptr. 205, 207, 178 Cal. App.2d 622, 625 (1960).
229People v. McCleod, 55 Cal. App. 4th 1205, 1217, 64 Cal. Rptr. 2d 545,
552 (1997)
230Smith, 45 Cal. 2d at 239, 288 P. 2d at 499.
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domicile requirement, people who have lived in California for years could be
excluded from the Act.
Second, interpreting the Act to exclude illegal aliens poses an equal pro-
tection problem. The Supreme Court has held that although illegal aliens do
not constitute a suspect class, the due process protection covers illegal aliens.23'
Even if a distinction between groups does not target a fundamental right or
burden a suspect class, the distinction must bear a rational relation to some
legitimate end.232 California will have a dicult time showing any legitimate
end served by not covering illegal aliens under the Compassionate Use Act.
Furthermore, the State of California would surely fail to demonstrate an intent
by the drafters of the Act to exclude illegal aliens, thus hindering its ability to
articulate a legitimate end.
The most problematic issue for initiative drafters to consider is how limiting a
state's medical marijuana exemption to state residents will be aected if several
neighboring states pass similar initiatives. One could end up with a situation
where two adjoining states allow medical marijuana use, but patients would
still be unable to use marijuana while visiting the other state. Drafters need to
protect against abuses of people crossing borders to get marijuana, but should
avoid using a residency requirement.
~ Initiative Drafters Should Avoid Giving Legislatures Control over
the Implementing the Initiative
In California only voters can modify voter approved initiatives. This rule
proved valuable when Assembly Member Margett introduced a bill that would
have thwarted Proposition 215. The bill dened primary caregiver as a blood
relative or in-law of the patient, thus excluding
231Plyer v. Doe, 457 U.S. 202, 210-212, 102 S.Ct. 2382, 2391-2392.
232Romer v. Evans, 116 S.Ct. 1620, 1627 (1996).
233Cal Assembly Bill 610 (1997).
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domestic partners and other good friends?34 It also required marijuana to
be grown only by state licensed growers who paid a $20,000 licensing fee, thus
excluding any patients from growing their own marijuana.235 Finally, it dened
the term recommend to mean prescribe and required marijuana to be distributed
through a licensed pharmacy, which would have eectively exposed physicians
and pharmacists to federal prosecution and sanction.236 The Attorney General
opposed the bill on the grounds that California law did not allow the legislature
to alter voter approved initiatives.237
Arizona's initiative did not have such protections and its legislature gutted
the medical marijuana provisions, necessitating a second initiative campaign.
The lesson drafters should take from these experiences is to avoid giving au-
thority to the legislature. State rules regarding legislatures' power to alter cod-
ied initiatives vary. Nonetheless, drafters should be wary of any clauses that
expressly allow the legislature to involve itself in the initiative's implementation.
e. Importance of Textual Precision
Drafters should be very careful and precise in their wording and have prospec-
tive initiatives reviewed by lawyers and as many outside readers as possible. A
poorly worded initiative, no matter how good its supporters' intentions are, has
the potential to cause more harm than good. This following illustration does not
appear to pose a danger, given the courts' sympathetic view toward Proposition
215, but it shows the need for care.
2341d.
235Id
237Letter to the Honorable Bob Margett from California Attorney General
Dan Lungren dated March27, 1997.
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While the illustration is California specic, the lesson future drafters can
leam is universal. Proposition 215's text protects patients and primary care-
givers from marijuana laws upon the recommendation or approval of a physician.238
This language indicates that recommendation and approval are two distinct ac-
tivities. The California Attorney General
interprets the two words as: approve is to validate an action already taken..,
while recommend
,,239
Using the Attorne
is the act of suggesting taking an action. y General's denitions, a
patient
who begins using marijuana on the recommendation of a physician, and
a patient who is already using marijuana and merely receives approval of a
physician are both covered by the Act. Thus, the Act provides no penalty for
not waiting for a physician's recommendation. On the other hand, a physician
may not be punished for having recommended marijuana to a patient for medical
purposes. The Act does not mention approval. While First Amendment issues
arise because an approval is even farther removed from a prescription than a
recommendation, the Attorney General notes the omission of the term approve
as signicant and maintains that physicians who approve the use of marijuana
by a person already doing so is not protected under the Act.2 ~
While the Attorney General's interpretation is not binding on any court, and
probably would fail in a prosecution of a physician who approved marijuana,24'
drafters of other initiatives should leam from this issue the importance of pre-
cision in technical language. Waiting for case
238Cal. Health & Safety Code x11362.5(d).
239Cal. Att'y General's Oce, Proposition 215: An Analysis (Dec. 20,
1996) at 3.
2401d. at 3, 8 (a physician who merely approves a self-prescribed use has no
defense).
241A number of powerful arguments could be brought to bear against the
Attorney General~s interpretation, including First Amendment rights and leg-
islative intent analysis. Most importantly, by the Attorney General's own de-
nition, the act of recommending is more acti~ e than approving.
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law to clarify an issue is extremely inconvenient for at least one individual{
the one pursuing their case through the appellate system.
3. Potential Problems that have not yet Become Problematic
The California initiative has provided future drafters with a real world lab-
oratory from which to observe and learn. Not all potential problems, how-
ever, have emerged. The following two issues have not proven problematic,
even through a negative interpretation by the Attorney General. Nevertheless
drafters should take notice of the potential problems when drafting their initia-
tives.
a. Requirements That the Patients Health Benet.
The rst section in Proposition 215, which expresses the intent of the drafters,
expresses an intent that patients be protected when marijuana use has been rec-
ommended by a physician who has determined that tJ~ persons's health ~u14
benet. (emphasis added)242 This language is dangerous because determining
that a patient ~~il4 benet puts a heavy burden on a physician. While the At-
torney General interprets the statute to require a physician to act in a medically
sound manner,243 one could argue that physicians would not be protected by
the statute unless they knew for sure that the patient would benet. This re-
quirement goes beyond sound medical practice. Physicians often try more than
one drug on a patient, experimenting to see which one will work. Furthermore,
some patients have adverse reactions to even the most benign drugs. Requiring
a physician to know anything for sure about a treatment is a daunting demand.
Future drafters of initiatives should consider toning down the language to re-
quire a physician to act in a medically sound manner or determine that they
reasonably expect the patient to benet.
242Cal. Health & Safety Code x 11 362.5(b)(A)
243 Cal. Att'y General's Oce, Proposition 215: An Analysis (Dec. 20,
1996) at 6.
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b. Severability
Proposition 215 included a severability clause protecting the remainder of the
initiative if part were deemed invalid by a court. One can view such a clause in
two ways. First, on the other hand, a partially functioning initiative may indeed
be preferable to pursuing a campaign for a second initiative. Furthermore, if an
initiative contains a distribution system, a severability clause can save it if the
distribution system is preempted. California has illustrated that an initiative
can work without a distribution system. Also, one would not want an eective
initiative struck down due to an insignicant part being invalidated.
On the other hand, if part of the initiative is deemed invalid, such an ac-
tion may negatively impact the entire initiative. Merely passing the initiative
achieved the rst two goals involved in the state medical marijuana initiative
campaign: to get it passed and send a message to the federal government. It
may be preferable to run a new initiative than live with a partially function-
ing one, and voters may be less likely to approve a new one if they think they
still have one that works well enough. Notwithstanding the potential problems,
thc benets to a severance clause outweigh the potential problems and drafters
should seriously consider including one.
V. Analysis of State Initiatives Currently Being Advanced by Spon-
sors
The following portion of this paper analyzes the various state initiatives
currently on ballots or in the signature gathering phase of placing them on
ballots. Some states have more than one initiative as some groups have cho-
sen not to work together. Americans For Medical Rights (AMR) is currently
promoting initiatives in six states, Alaska, Colorado, Maine, Nevada,2 Oregon,
and Washington D.C.. States that have non AMR initiatives being promoted
include Alaska, Colorado, Florida, Maine, Washington, and Washington D.C..
Therefore, I have
2Nevada is AMIR's latest initiative. Its text is included, but it was not
received in time to include a discussion of it in this paper.
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divided this section into AMP. initiatives and non-AMIR initiatives. Because
a number of AMIR initiatives are similar, I will use the Colorado initiative as a
model, and then note how the other initiatives follow or diverge from it.
The following descriptions do not fully elaborate on the technical details of
the initiatives. They are intended to provide a summary understanding of each
one. Footnotes to specic clauses and sections enable closer examination of the
initiatives when a summary invokes questions or does not provide the desired
detail.
This section also includes a discussion of interesting, unique, or problematic
provisions drafters have included in the various initiatives. When a provision
raises an issue discussed in the section on lessons leamed from the California and
Arizona initiatives, the discussion is supercial to avoid redundancy. In some
cases, a provision or lack thereof does not warrant any additional discussion,
such as the inclusion or omission of a severance clause or provision relating to
minors. Additionally, most initiatives include the basic requirements necessary
to protect patients, physicians, and in most cases primary caregivers. These
provisions generally require no special discussion. As a result, the analysis of
current initiatives may appear excessively negative. The purpose of the analysis
is not to disparage the initiatives, or assert that they are poorly drafted. It is,
however, intended to subject them to a critical evaluation.
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A. AMR Initiatives
1. Colorado
Background
AMR's Colorado initiative amends Article XVIII of the Colorado Consti-
tution. It is presently in the signature gathering stage with signatures due in
August.
Registry and Identication Card
The Colorado initiative requires the governor to designate a state health
agency (Agency) to establish a condential patient registry of individuals who
have applied for approval to use marijuana for medical purposes.245 If a pa-
tient's application is approved, the agency issues a registry identication card
identifying the patient and the patient's primary caregiver as certied to engage
in the use of marijuana for medical purposes.2 ~ This card (or proof of applica-
tion for a card241) protects the patient and primary caregiver from arrest and
prosecution.24S Access to information contained in the registry is restricted to
authorized employees of the Agency and state or local law enforcement agencies
seeking to verify the validity of a card presented to them.249
Applications for registration must include: (1) written documentation show-
ing a diagnosis of a debilitating medical condition and the physician's conclusion
that the patient might benet from the medical use of marijuana; (2) the pa-
tient's name, address, date of birth, and social
245Coloradans for Medical Rights (CMR), Colorado, Amendment for Medical Use of Marijuana,
x14(7).
246CMR-Colorado, x 14(3)(c).
247CM1R-Colorado, x 14(3)(d).
248CMR-Colorado, x 14(3)(a).
249CMR-Colorado, x 14(3)(a).
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security number; (3) the name, address and telephone number of the pa-
tient's physician; and (4) the name and address of the patient's primary care-
giver (if any).250 The Agency may not reject an application without a legitimate
reason,25' and failure by the Agency to approve or reject an application within
thirty-ve days results in the application's automatic approval.252
The initiative includes various administrative rules directed at how the pro-
gram functions. For example, the agency may charge a reasonable fee to cover
the administrative costs of the program.253 Also, if an application is denied, pa-
tients may not reapply to the registry for six months.254 Patients must submit
updated written documentation and information on their primary caregivers
on an annual basis.255 Finally, state employees are required to notify the state
health agency of violations of the medical marijuana law.256
Non-registry Exemption
Participation in the patient registry program is not mandatory. The initia-
tive also provides an armative defense to individuals who can show that they
have been diagnosed with a debilitating medical condition and their physician
advised them (orally or in writing) that they
257 advan
might benet from marijuana. The tage of participation in the registry is
that a police ocer may not arrest patients for possession of marijuana once
they show their registry
250CMR-Colorado, x 1 4(3)(b).
251CM1R-Colorado, x 14(3)(c).
252CM1R-Colorado, x 1 4(3)(d).
253CMR-Colorado, x 14(3)(i).
254CM1R-Colorado, x 1 4(3)(e).
255CM1R-Colorado, x 14(3)(f).
256CM1R-Colorado, x14(3)(g).
257CM1R-Colorado, x 14(3)(a).
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identication cards. Those who choose not to participate in the registry are
subject to arrest and carry the burden of proof at trial.
Limitations
Patients using medical marijuana are limited to two ounces of marijuana in
useable form or six plants, of which no more than three may produce useable
marijuana at any one time.258 Patients or primary caregivers in possession of
more than the allowed amount may be arrested, but have an armative defense
if they can show that the greater amount was medically necessary.259 Further-
more, the initiative explicitly states that non-medical marijuana is not covered
under this initiative, even for approved patients.260
Restrictions on Use
Patients are restricted from using medical marijuana in public or in a way
that would endanger others. Patients who violate these restrictions will lose
their identication cards for a year.261 The initiative also states that it does not
require employers to accommodate medical use of marijuana at work.262
258CM1R-Colorado, x 1 4(4)(a).
259CM1R-Colorado, x 1 4(4)(b).
260CMR-Colorado, x 1 4(2)(d).
261CM1R-Colorado, x 14(5). The initiative does not indicate whether pa-
tients who lose their registry identication cards for a year due to discipline may
still take advantage of the non-registry exemption. The plain language of the
text found in x14(5)(b) merely states that a patient who violates the restrictions
on medical use under x14(5)(a) may not use an identication card for a year.
On the other hand, the non-registry exemption specically states that it applies
[e]xcept as otherwise provided in subsection[] 5. One could argue that since the
one year suspension of the identication card is in subsection 5, one loses all
rights to use marijuana for medical uses. It is impossible to predict how a court
would rule on this issue.
262CMR-Colorado, x14(l0)(b). It is interesting to note that the initiative
does not require employees to accommodate marijuana use, whereas the initia-
tive explicitly prohibits the public use of marijuana. Therefore, the state could
still allow marijuana to be used in these situations,
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Physician Liability
Physicians are free from prosecution for advising bona-de patients about
the risks and benets of medical marijuana, and from providing the written
documentation required for application to the registry, as long as the advice
is based on an assessment of the patient's medical history and current medical
condition.263 Physicians are also free from prosecution or discipline for providing
the written documentation required for application to the registry. Minors
Minors are excluded from the non-registry exemption clause and must adhere
to the following requirements:
1. Diagnosis of debilitating medical condition by two physicians;
2. Explanation by one of the physicians to the patient and each
parent residing in Colorado of the risks and benets of using marijuana;
3. Written documentation provided by physician indicating that the
patient might benet from marijuana;
4. Written consent of each parent residing in Colorado;
5. A parent who is a resident of Colorado must agree to be the
primary caregiver;
6. Application and receipt~ of a registry identication card;
7. Possession limitations apply to parent and minor collectively;
8. The parent must take responsibility for controlling the use of
marijuana.265
but it is not required to do so. Conversely, the state would have to change
the law if it wanted to allow the use of marijuana in public.
263CM1R-Colorado, x 1 4(2)(c).
2&lFor adults, proof of application to the registry is sucient to prevent
arrest, while minors must have received the registry identication card.
265CM1R-Colorado, x 14(6).
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Miscellaneous Provisions
 No property forfeiture is allowed unless it is in connection with
a criminal conviction or a guilty plea. Marijuana and its paraphernalia must
be returned upon determination that a suspect may use marijuana for medical
purposes. A decision not to prosecute, dismissed charges, and acquittals are all
evidence of eligibility to use marijuana.266
 No governmental or private health insurance providers can be re-
quired to pay for the cost of marijuana for medical uses.267
 The initiative requires the General Assembly to enact criminal
penalties for fraud committed in connection with the laws created by this
initiative.268
 No severability clause.
Denitions
Debilitating medical condition means:
(1) the following diseases: cancer, glaucoma, HIV+, AIDS;
(2) diseases which produced one of the following symptoms: cachexia269,
severe pain, severe nausea, seizures (including those characteristic of epilepsy),
muscle spasms (including those characteristic of multiple sclerosis);
(3) The Agency has authority to include other medical conditions.270
Primary caregiver means a person eighteen years of age or older who has
signicant responsibility for managing the well-being of a'
266CM1R-Colorado, x 14(2)(e).
267CM1R-Colorado, x 14(10).
268CMR-Colorado, x 14(8).
269Physical wasting and malnutrition. Merriam Webster's Collegiate Dictio-
nary 159 (10th ed. 1994).
270CMR-Colorado, x 14(1 )(a).
271CIvJJ~~Colorado x 14(1 )(f).
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'Usable form' and 'usable marijuana' means the seeds, leaves, buds, and
owers of the plant (genus) Cannabis, but does not include the stalks, stems,
or roots.272
'Written documentation' means a statement signed by a patient's physician
or copies of the patient's pertinent medical records.273
2. Alaska Background
In Alaska, marijuana is schedule VIA, which means it has the lowest degree
of danger.274 This initiative amends Alaska Statutes x 11.71.190 to exempt
marijuana possessed for medical purposes from the list of Schedule VIA drugs.275
The rest of the initiative amends Title 17, Chapter 35 of the Alaska Statutes.
As of April 2, 1998 the Alaska initiative is in the supplemental period. The
initiative fell 1,000 signatures short but AMIR has 3,000 more to turn in.276 It
should be on the November 1998 ballot.
272CM1R-Colorado, x 14(1 )(i).
273CM1R-Colorado, x 14(1 )(.j).
274Alaska Stat. x11.71.190
275Alaskans for Medical Rights (ALMR), Alaska, Bill Allowing Medical Use of
Marijuana. x2 AS 11.71.190(b).
276 Telephone interview with Dave Fratello, Spokesperson, Americans For
Medical Rights (January 16, 1998).
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Registrv and Identication Card
The Alaska initiative establishes a condential patient registry in the same
format as the model Colorado initiative with a few dierences.277 It does not
include the requirement that state employees report patients for violations of
the medical marijuana law, yearly renewals, or a waiting period before one may
reapply after being denied.
Non-registry Exemption
Just as in the model initiative, patients also have the armative defense op-
tion. Therefore, participation in the patient registry program is not mandatory.278
Limitations
Patients are limited to one ounce of marijuana (as opposed to two ounces in
the model initiative) or six plants (the same as in the model), of which no more
than three may produce useable marijuana at any one time.279 Individuals in
possession of more than the allowed amounts are not excepted from the criminal
laws (they can be arrested), but they can provide an armative defense at trial
that they needed more than the allowed amounts.280 The initiative parallels the
model initiative in its lack of protection for non-medical marijuana use.28'
277ALMIR-Alaska, x 1. AS 17.35.010; (a)-(b) (condentiality of registry); (c)
(requirements of application); (d) (issuance of registration card); (e) (automatic
approval if not rejected); (h)(i) (reasonable administrative fee allowed); (b)
(identication card protects patient from arrest); AS 17.35.010 (e) (proof of
application sucient to protect patient from arrest).
278No written documentation would be required. ALMIR-Alaska, x1. AS
17.35.030 (a).
279ALMIR-Alaska, x1. AS 17.35.020 (a).
280ALMR-Alaska, x1. AS 17.35.020 (b).
281ALMR-Alaska, x1. AS 17.35.030 (d).
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Restrictions on Use
In addition to the model initiative's restriction against using medical mari-
juana in public or in a way that would endanger others, it also prohibits patients
from distributing marijuana to any person who is known to the patient not to
be either in lawful possession of a registry identication card or eligible for such
card.282 Patients who violate these restrictions would lose their identication
cards for one year.283
The initiative does not require accommodation for medical use of marijuana
at work, in correctional facilities, within 500 feet of a school, within 500 feet of
a recreation or youth center, or on a school bus.284
Physician Liability
Physicians are free from prosecution or discipline for advising bona-de pa-
tients about the risks and benets of medical marijuana as long as the advice is
based on an assessment of the patient's medical history and current medical con-
dition. Physicians are also be free from prosecution or discipline for providing
the written documentation required for application to the registry.
282The language of the initiative appears to avoid placing a burden of veri-
cation on the patient. It prohibits a patient from distributing marijuana to a
person the patient knows is not eligible to use it, as opposed to prohibiting dis-
tribution if the patient is unaware of the person's eligibility. The wording of the
initiative appears to permit ignorance as an excuse. There is a high probability,
however, that courts will require some level of care. Alaska, x1 AS 17.35.040
(a).
283 See CMR-Colorado discussion at note 17 regarding the issue of whether
patients still have
an armative defense if their registrations have been revoked. See also
ALMR-Alaska, x 1. AS
17.35.030(a), 17.35.040.
284ALMIR-Alaska, x 1. AS 17.35.040 (d). ~ CMR.-Colorado discussion at
note 18 regarding the dierence between prohibiting certain acts versus not
requiring the state to accommodate certain act.
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Minors
Minors are excluded from the non-registry exemption clause and must adhere
to the following guidelines, which dier slightly from the model:
1. Diagnosis of debilitating medical condition;
2. Explanation by the physician to the patient and one parent or
guardian residing in Alaska of the risks and benets of using marijuana;
3. Written documentation from the physician that the patient might
benet from marijuana;
4. Written parental consent;
5. Written parental agreement to act as primary caregiver;
6. Application and receipt of a registry identication card;285
7. Possession limitations apply to parent and minor collectively;
8. Parent must take responsibility for controlling the use of marijuana.286
Miscellaneous Provisions
 The same property forfeiture prohibition as in the model applies.287
 As in the model, no governmental or private health insurance
providers can be required to pay for the cost of marijuana for medical uses.288
285 For adults, proof of application to the registry is sucient to prevent
arrest, while minors must have received the registry identication card.
286ALMR-Alaska, x 1. AS 17.35.050.
287ALMIR-Alaska, x 1. AS 17.35.030(e).
288The language of the initiative appears to avoid placing a burden of ver-
ication on the patient. It prohibits a patient from distributing marijuana to
a person the patient knows is not eligible to use it, as opposed to prohibiting
distribution if the patient is unaware of the person's eligibility. The wording of
the initiative appears to permit ignorance as an excuse. There is a high proba-
bility, however, that courts will require some level of care. ALMR-Alaska, x 1.
AS 17.35.040 (c).
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Denitions
The Alaska initiative's denitions for debilitating medical condition, primary
caregiver, and written documentation are the same as those in the model.289
The model initiative's denition of usable marijuana excludes stalks, stems and
roots, while the Alaska initiative excludes only stalks and roots.200
3. Oregon
Background
The Oregon initiative is in the signature gathering process and signatures
are due on July 3rd, 1998.
Registry and Identication Card
The Oregon initiative establishes a condential patient registry in the same
format as the model Colorado initiative, established and administered by the
Health Division of the Oregon Department of Human Resources.29' The only
dierence is that this initiative does not require the registry to include names
of people who have applied for the registry but have not yet been approved.
289ALMR-Alaska, x1. AS 17.35.070.
200ALMiR-Alaska, x1. AS 17.35.070 (j).
291Oregonians for Medical Rights (OMR), Oregon, The Oregon Medical Marijuana Act,
x4(2), x 12(1). Oregon x4(1) (identication card protects patient from arrest);
x4(2) (requirements of application); x4(2) (reasonable administrative fee al-
lowed); x4(6)(a) (approval required within ve days if no cause to deny exists);
x4(9) (proof of application sucient to protect patient from arrest); x 12(2)
(condentiality of registry).
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Non-registry Exemption
The patient registry program is optional because the Oregon initiative pro-
vides an armative defense for patients who would otherwise be eligible for
the registry.292 This armative defense, however, is not available to primary
caregivers, who are not permitted outside the context of the registry system.293
Therefore, registration is mandatory for any patient who needs a primary care-
giver, to the extent that the patient wishes to protect the primary caregiver
from prosecution.
Limitations
Patients may only use marijuana for medical purposes.294 The initiative
limits patients and primary caregivers collectively to the following amounts of
marijuana:
1. If in a location where marijuana is not produced, one ounce of
usable marijuana;
2. If in a location where marijuana is produced, three mature plants,295
four immature plants and one ounce of usable marijuana per mature plant.2 ~
The initiative provides an armative defense similar to the model for amounts
exceeding the limitation.297
2920MR-Oregon, x6(1).
2930M1R-Oregon, x3(10).
2940M1R-Oregon, x7(1).
295The Health Division shall dene mature and immature. OMR-Oregon,
x7(3).
2 ~OMR-Oregon, x7(1). Usable marijuana is dened as dried leaves and ow-
ers, so the mature plants would not count as useable marijuana.
2970MR-Oregon, x7(2).
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Restrictions on Use
Patients using medical marijuana are still subject to the following restrictions
and may be criminally prosecuted for the following violations:
1. Driving under the inuence of marijuana;
2. Using marijuana in a public place;
3. Delivering marijuana to any individual known not to be in pos-
session of a registry identication card;298
4. Selling marijuana to anybody, including one in possession of a
registry identication card.2 ~
6. Violating any other provision of the initiative.300
Patients who violate these restrictions may lose their identication
cards for six months.30' The initiative does not require accommodation for med-
ical use of marijuana at work.302
Physician Liability
Physicians are not be subject to civil liability or professional discipline for
advising people about the risks and benets of using marijuana for medical
purposes, for advising people that marijuana may help their conditions, or for
providing written documentation that marijuana
298 See ALMR-Alaska discussion at note 282 regarding the level of care a
patient must take to verify a recipient's registry identication card.
2 ~OMIR-Oregon, x5
3000MR-Oregon, x 11
301 See CMIR-Colorado discussion at note 261 regarding the issue of whether
patients still have an armative defense if their registrations have been revoked.
See also OMR-Oregon,
xx5(2), 6(1).
3020M1R-Oregon, x 16(2).
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may help their conditions, if such advice is based on a personal assessment
of the person's medical history and current condition.303
Minors
Minors may receive a registry identication card. In addition to the stan-
dard requirements, one of the minor's parents or guardians must sign a written
statement indicating the following:
1. The physician explained to the patient and one parent or guardian
the risks and benets of medical marijuana;
2. The parent consents to the minor's use of marijuana;
3. The parent agrees to serve as primary caregiver;
4. The parent will control the use of marijuana.304
Miscellaneous Provisions
 Possession of a registry identication card does not give law en-
forcement probable cause to search people or their property.305
 The property forfeiture restrictions are the same as those in the
model initiative's.306
 As in the model, no governmental or private health insurance
providers can be required to pay for the cost of marijuana for medical uses.307
 Professional licensing organizations may not discipline its licensees
for using medical
marijuana or acting as a primary 308
 Severability Clause309
3030M1R-Oregon, x9.
'040M1R-Oregon, x4(3).
3050MR-Oregon, x8(1).
3060M1R-Oregon, x 8(2).
3070MR-Oregon, x 16(1).
3080M1R-Oregon, x 10.
3090M1R-Oregon, x 18.
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Denitions
The Oregon initiative's denitions for debilitating medical conditionand writ-
ten documentation are the same as those in the model initiative.310
Usable marijuana means dried leaves and owers of the plant Cannabis fam-
ily Moraceae, excluding seeds, stalks and roots.31'
Designated primary caregiver means an adult who has signicant respon-
sibility for managing the well-being of a patient and has been designated as
such on the patient's application for a registry identication card or in other
written notication to the Health Division of the Oregon Department of Human
Resources.312 A person may not have more than one primary caregiver.313
4. Washington D.C.
Background
The initiative amends Title 33 of the Washington D.C. Code. It is currently
in the signature gathering stage.
Registry and Identication Card
There is no provision for a registration system.314
Non registry Exemption
The initiative provides an armative defense for patients and primary care-
givers charged with violating District marijuana laws when the patients have
been diagnosed with a debilitating
3100MR-Oregon, x3(1), (11).
3110MR-Oregon, x3(10). Note that the Alaska denition does not exclude
stems but the Colorado denition does.
3120MR-Oregon, x3(4).
3130MR-Oregon, x 13(2).
3140n privacy grounds, ACT UP opposes any system that would require
patients to register with the government. Telephone interview with Paul Wolf,
ACT UP (January 17, 1998).
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medical condition and were advised by their physicians that they might
benet from using marijuana.315 No written documentation is required.
Limitations
The Washington D.C. initiative does not specify limitations on the amount
of marijuana a patient may posses. It limits patients and primary caregivers col-
lectively to an amount necessary under the circumstances or 60 days, whichever
is less.316 The initiative does not cover non-medical marijuana, even for patients
approved for medical use.317 Restrictions on Use
Just as with Alaska and Colorado, patients are restricted from using mari-
juana in public or in a way that would endanger others.318 The initiative also
explicitly states that it will not negate the mens rea for any oense or provide a
defense to any crimes involving violence, danger to others, or operating motor
vehicles while impaired.319
The initiative does not require any accommodation for medical use of mari-
juana by an employer, on school grounds, at a recreation or youth center, or on
a school bus.320
315D.C. Voters for Medical Rights (DCMIR), Washington D.C., Medical Use of
Marijuana Initiative of 1998, Chapter 11 x33-1102 (a).
316DCMIR-D.C., x33-1104 (a). This provision is a product of negotiations
between AMP. and ACT UP. ACT UP felt that AMIR's typical limitations were
too restrictive and could inhibit patients' ow of marijuana, forcing them onto
the black market. Telephone interview with Paul Wolf, ACT UP (January 17,
1998).
317DCMIR-D.C., x33-1102 (d).
318DCMIR-D.C., x33-1105 (a).
319D.C., x33-1 105 (b).
320DCMR-D.C., x33-1105 (d). See CMIR-Colorado discussion at note 262
regarding the dierence between prohibiting certain acts versus not requiring
the state to accommodate certain act.
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Physician Liability
In language comparable but not identical to the model initiative, the ini-
tiative protects physicians from prosecution or discipline for advising bona-de
patients about the risks and benets of medical marijuana and for providing
written documentation stating that the patient might benet from the medical
use of marijuana.32' A clause unique to the Washington D.C. initiative allows
physicians called to testify in court to do so in camera and request their names
be kept condential and redacted from public documents.322
Minors
Minors may not use marijuana for medical purposes unless the following
guidelines are met.
1. Diagnosis of debilitating medical condition by t~ physicians;
2. Explanation by one of the physicians of the risks and benets to
the patient and each parent or guardian residing in the District;
3. Advice by one of the physicians that the patient might benet;
4. Parental consent by each parent residing in the District of Columbia;
5. One parent agrees to serve as primary caregiver;
6. Possession limitations apply to parent and minor collectively;
7. Parent controls the use of marijuana.323
321DCMR-D.C., x33-1102 (b).
322DCMIR-D.C., x33-1 105 (c). Due to federal supremacy, a physician called
to testify on behalf of a patient prosecuted under federal law would probably
not remain anonymous.
323DCMR-D.C., x33-1106
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Distribution
The Director of the District of Columbia Department of Health shall develop
a plan to provide marijuana to eligible patients. The plan must allow for non-
prot buyers clubs to operate and provide for aordable distribution to all
patients covered by Medicaid or a Ryan White CARE Act-funded program.324
Miscellaneous Provisions.
 The property forfeiture restrictions are the same as those in the model
initiative.
 No private health insurance providers can be required to pay for
the cost of marijuana for medical uses.325
 Severability clause.326
Denitions
Debilitating medical condition and written documentation have the same
denition as the model initiative.327
Primary caregiver means an adult who has signicant responsibility for man-
aging the well being of a patient. A patient may not have more than one primary
caregiver without a showing of
328
necessity.
The initiative has no denition of useable marijuana. It denes marijuana
as the plant genus Cannabis.329
324DCMR-D.C., x33-1103
325Contrary to the model initiative, the government is excluded from this
clause because the initiative specically includes Medicare and the Ryan White
CARE programs. DCMR-D.C., x33-1105 (c).
326DCMIR-D.C., x33-1 109.
327DCMR-D.C., x33-1101 (1), (9).
328DCMIR-D.C., x33-1 101 (7).
329DCMR-D.C., x33-1101 (8).
8583
5. Maine Background
This initiative enacts new language and also amends the language of various
existing statutes to achieve its purpose. The Maine initiative fell 4,000 signa-
tures short of the number required to place it on the ballot. AMP. is currently
challenging the state's decision not to put the initiative on the November 1998
ballot.330 It will certainly be on the November 1999 ballot because signatures
carry to the next year, giving AMIR a year to collect 4,000 more signatures.
Requirements
Persons at least eighteen years of age may lawfully possess marijuana for
medical use if they meet certain conditions. First, the patient must be diagnosed
by a physician with one of the following conditions: nausea; vomiting; wasting
syndrome or loss of appetite due to AIDS or cancer treatments; glaucoma;
seizures associated with diseases such as epilepsy; or muscle spasms associated
with diseases such as multiple sclerosis.33' Second, the patient's physician must
discuss the risks and benets of marijuana, provide a professional opinion of the
balance of risks and benets, and advise the patient that the patient may benet
from marijuana.332 Third, patients must disclose their medical use of marijuana
to their physicians and remain under the physician's continuing care.333
330 Telephone interview with Dave Fratello, Spokesperson, Americans for
Medical Rights (April 2, 1998).
331Mainers for Medical Rights (MMR), Maine, An Act to Permit the Medical Use of Marijuana,
x10 (5)(A)(l).
332MM1R-Maine, x 10 (5)(A)(2).
333M1vIR-Maine, x10 (5)(A)(3), (4).
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Limitations
A patient may not posses more than 1 1/4 ounces of harvested marijuana
and six plants, of which no more than 3 may be mature, owering plants.334
Restrictions on Use
A patient may not use marijuana in public or at work when prohibited.335
Physician Liability
A physician may not be disciplined for advising patients that they might
benet from the medical use of marijuana.336
Minors
Minors may use medical marijuana if, in addition to meeting the require-
ments for patients over 18 years of age, the minor patient has written parental
consent.337
Miscellaneous Provisions
The initiative prevents the forfeiture of property based on the medical use
of marijuana.338 Denitions
Designated caregiver means a person over 18 years of age who is a family
member or other person who has consistently assumed responsibility for a per-
son's housing, health or safety and is either the patient's legal parent or guardian
or has been designated in writing by the patient as
334MMR-Maine, xx10 (5)(A), 9.
335M1MR-Maine, x10 (5)(F).
336MMR-Maine, x 10 (F).
337MMR-Maine, x10 (5)(B).
338MMR-Maine, x3.
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his or her designated caregivel939 Designated caregivers may lawfully possess
a usable amount of marijuana to provide to the patient.340
6. Evaluation of AMR Initiatives
AMIR has taken a conservative strategy with its initiatives. One of its pri-
mary goals is to draft initiatives that voters will pass and that will avoid federal
pre-emption. It sees the pressure exerted on the federal government caused by
voters approving initiatives as more powerful in the long term than the actual
provisions in an initiative. Furthermore, an initiative that is invalidated under
federal supremacy provides only initial inuence, but fails to apply continuous
pressure on the federal government. While other initiatives may provide better
protection for patients, AMIR has taken the position that the risk of harm re-
sulting from an initiative's election failure or subsequent invalidation outweighs
the benet it would provide to the patient if the initiative stood. While reason-
able minds can disagree, AMIR's position is rational.
a. Evaluation of AMR's Colorado Initiative
AMIR's Colorado initiative shows good textual precision. The only un-
certainty I noticed was whether patients who lose their licenses also lose the
armative defense, thus preventing them from using marijuana for medical
purposes during their suspension.34' Nuances in the initiative also demonstrate
that AIvIR chose its words carefully. For example, it distinguished between
cases where it prohibits certain acts and where it does not require the state to
allow
3391vllv1R-Maine, x7 A- 1.
340MMR-Maine, x10 (C). The initiative does not aggregate the amount of
marijuana possessed by the patient and primary caregiver as in the other AMIR
initiatives. One may reasonably read the initiative to allow for 2 1/2 ounces of
harvested marijuana and 12 plants between the patient and designated caregiver.
i' See CMR-Colorado discussion at note 261 regarding the issue of whether
patients still have an armative defense if their registrations have been revoked.
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certain acts. Also, it allows adults to use marijuana from the time they
apply to the registry, but requires minors to wait for approval. These subtleties
demonstrate that AMR gave careful consideration to, and anticipated ramica-
tions from, its choice of wording.
AMIR's Colorado initiative (as well as its other initiatives) takes an inter-
esting approach to physician liability. It does not use the word recommend and
appears to require less active encouragement than a recommendation would
connote. For patients to conform to the law, their physicians must discuss the
possible risks and benets of using marijuana with them and provide a pro-
fessional opinion or conclusion that the patient might benet from the use of
marijuana (the benets may outweigh the risks). Such a requirement appears
to require nothing more than an admission or expression of a medical opinion
by a physician. This approach may help shield doctors from DEA sanctions
better than the term recommend by bringing them more securely under the
First Amendment. The drawback of this approach is that it opens the initiative
to attack by opponents who will probably argue that not only is no prescrip-
tion required, physicians do not even have to recommend its use; they must
merely opine that it may help. If the initiative can succeed with the voters, this
provision will be an excellent protection for physicians.
Probably the most controversial aspect of the Colorado initiative is its regis-
tration system. The registration experiment in Arcata, California has received
considerable praise, and even guarded optimism from the California Attorney
General's oce.342 This system protects patients from arrest, as opposed to
protecting them from conviction through an armative defense. Without a
registration system police are generally free to arrest a patient because an ar-
mative defense is one that a defendant raises at trial. The question of whether
the marijuana use was medical is a question of fact, the answer to which is
decided by a jury. Police need not answer
342Kate Rix, Grass Rots Take Hold of Prop 215, The Recorder, March 11,
1998, 1.
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that question in the eld. On the other hand, under a registration system,
the police must show a reasonable belief that the patient is not complying with
the law. Furthermore, the system is voluntary and patients who do not want
to register may still avail themselves of the armative defense. Therefore, a
registration system provides greater protection for patients.
On the other hand, ACT UP and other AiDS groups are opposed to any
system that keeps records on patients with AIDS.343 This opposition stems from
the fear of persecution and discrimination against AIDS patients. ACT UP' s
fear materialized recently when police seized the patient records from the Santa
Clara County Medical Cannabis Center during their criminal investigation into
the club.3 While patients could choose not to register and avail themselves of
the armative defense, ACT UP fears that the existence of a registry program
would hurt those who did not register. For example, police would assume that
legitimate users would have no reason not to register; therefore, they would
be more likely to arrest an unregistered patient than if no registration system
existed.345 Also, the federal government could conceivably overrule the state's
condentiality requirements and demand access to the records so they could
investigate the patients for federal crimes. AMR appears to rely on political
restraints to prevent such breaches of the registry's condential protections.
A registration system has an enormous potential to protect patients. On the
other hand, it raises legitimate privacy concerns. The issue of registration is
really a judgement call by drafters and voters. If an initiative drafter feels that
its benets outweigh its risks, AIn4iR has developed a well-thought-out system
worthy of emulation.
343Telephone interview with Wayne Turner, ACT UP (April 2, 1998).
3Russell Sabin, Medical Privacy at Issue in Pot Club Records Seizure, The
San Francisco Chronicle, April 2, 1998, A17.
345Telephone interview with Paul Wolf. ACT UP (January 17, 1998).
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In terms of what conditions qualify a patient to use marijuana, AMR chose
a balanced approach. It restricts the diseases to those enumerated in the ini-
tiative, but provides for the Agency to include new conditions. This approach
fends o the argument that the initiative permits marijuana use for any condi-
tion including writer's cramp without requiring a new initiative to include new
conditions. The drawback is that if the Agency is opposed to using marijuana
for medical uses, it may refuse to include new diseases.
One area where AMR chose an ill-advised strategy was in not including a
severability clause or a distribution system and placing limits on the amount
of marijuana patients and primary caregivers could possess and cultivate. For
the reasons discussed in Section IV E2, AMIR should have avoided placing enu-
merated limits on possession and cultivation. The initiative will not adequately
protect patients who grow their own marijuana; however, it oers patients no
alternative method of obtaining marijuana. The initiative does allow patients to
possess greater quantities, but places the burden to prove necessity on the pa-
tient. Providing patients an armative defense for more than two ounces or six
plants would defeat the purpose of the registration system, which is to protect
patients from arrest. The initiative relies too heavily on the anticipated polit-
ical pressure holding government ocials in check so that patients can obtain
marijuana. Granted, even initiatives that oer better protections for patients
only do so at the state level. The federal government's inability to enforce small
possession and cultivation violations of federal law, however, means that state
protections do oer real protections for patients. AMR should not have included
enumerated limits on amounts a patient may possess, should have included a
distribution system, and should have protected the rest of the initiative with a
severability clause.
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b. Evaluation of AMIR's Alaska Initiative
AMR's Alaska initiative is very similar to the Colorado initiative and subject
to the same praise and criticism. The Alaska initiative does have one provision
not included in the Colorado initiative that may prove problematic. It does
not require the state to allow use of medical marijuana within 500 feet of a
school, recreation center, or youth center. At rst glance, this provision appears
reasonable. It does not, however, address what might happen to patients who
live within 500 feet of one of these locations.
c. Evaluation of AMIR's Oregon Initiative
AMR's Oregon initiative is also patterned after the Colorado initiative; how-
ever, it has a problematic provision that may make registration compulsory.
Primary caregivers are dened as people who have been declared primary care-
givers on a patient's application for a registry identication card. Furthermore,
the provision that provides an armative defense to patients who choose not
to register does not provide such a defense to primary caregivers. Therefore,
patients who need primary caregivers must register if they wish to protect them
from prosecution. As I asserted earlier, the choice to include a voluntary regis-
tration system is a judgement call with either answer acceptable. A compulsory
registration system, however, is inappropriate and should not be included.
d. Evaluation of AMR's Washington D.C. Initiative
AMIR's Washington D.C. initiative diers from the traditional AMIR initia-
tive. Its text is a product of negotiations between AIvIR and ACT UP.3 ~ ACT
UP had failed in a petition drive to place initiative 59 on the ballot in 1997.
It resubmitted the essentially identical text which became initiative 59. When
AMIR expressed its intention to enter Washington D.C. using its
3 ~Telephone interview with Dave Fratello, Spokesperson, Americans for Med-
ical Rights (January 16, 1998).
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traditional language, ACT UP protested and the two groups met to nd a
text that both groups could support.347 They developed a mutually agreeable
language that both groups submitted separately to the District.348 Disagree-
ments later arose and ACT UP withdrew its version of the modied initiative
and is presently working to place initiative 59 on the ballot. AMIR is proceeding
with the compromise initiative.
AMR's policy is to avoid issues of distribution in its initiatives. Distribution
plans cause two problems from AMR's point of view. First, involving the state
in either distributing or sanctioning the distribution of marijuana poses political
risks.349 AMR's highest priority is to write legislation that can pass. Second, by
becoming involved in distribution, a state may nd itself in direct conict with
federal law, which can allow a court to overturn the initiative.350 AMR seeks to
pass bills that will remain on the books as opposed to bills that will come into
conict with federal law and be overturned.35'
Nevertheless, AMR did include a distribution system and severability clause
in its initiative as a result of the compromise with ACT UP.352 It exempts
buyers clubs from state marijuana laws and it requires the District Department
of Health to develop a distribution plan as well. The exemption for buyers clubs
is not susceptible to preemption because it does not
347Telephone interview with Dave Fratello, Spokesperson, Americans for
Medical Rights (January 16, 1998). Telephone interview with Paul Wolf, ACT
UP (January 17, 1998).
348Telephone interview with Wayne Turner, ACT UP (April 2, 1998).
349E-mail from Dave Fratello, Spokesperson, Americans for Medical Rights
to Don Christen, Maine Vocals (on le with author).
350E-mail from Dave Fratello, Spokesperson, Americans for Medical Rights
to Don Christen, Maine Vocals (on le with author).
~ Telephone interview with Dave Fratello, Spokesperson, Americans for Med-
ical Rights (April 2, 1998).
352 Telephone interview with Paul Wolf, ACT UP (January 17, 1998).
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conict with federal law. Buyers clubs would merely be exempt from state
law, yet still subject to federal law. The Department of Health distribution plan
is a closer call. The initiative requires the Department to develop a plan, so the
statute could avoid preemption under the argument that it requires a plan that
does not conict with state law. The plan could be quashed, however, because
it would necessarily cause the District to violate federal law. Nevertheless, the
provision provides the statutory authority to institute a plan as soon as the
federal government alters its policy.
AMR takes a dierent approach to limits on the amount of marijuana a
patient and primary caregiver may cultivate and possess. It limits the amount
to that which is necessary under the circumstances or sixty days. This restriction
is more realistic than the ones in the Colorado, Alaska, and Oregon initiatives.
It shelters the initiative from attacks claiming that it would allow enormous
amounts of marijuana, it avoids placing unreasonable restrictions on patients,
and it avoids the baggage of using the term personal use. The provision's
weakness is its sixty day supply limit. AMR should have permitted a ninety
day supply to allow patients to possess enough to last through an indoor growing
period. Allowing the one year supply for outdoor cultivation is neither necessary,
because Washington D.C.'s urban environment would not lend itself to outdoor
cultivation, not politically feasible.
e. Evaluation of AMR' s Maine Initiative
AMR's Maine initiative does not use the standard AMIR format and does
not include a registration program. Although it takes a more succinct approach,
it stays true to the AMR philosophy, such as addressing the issue of minors and
oering physicians increased protection.
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This initiative has several of the same weaknesses as well. It does not have
a distribution system or severability clause and its limits on possession are
unreasonably low. Also, in a departure from the other AMIR initiatives, it
restricts the medical conditions that qualify a patient to use marijuana without
providing a method to add a new condition when evidence supports its inclusion.
Such a provision is the best politically to ward o attacks that marijuana will be
used for every ailment imaginable. On the other hand, it is dangerous because
in the future, science may indicate a new use for marijuana that state law will
not permit.
B. Non-AMR Initiatives
1. Alaska Summary
The Alaska initiative adds Section 18.08.016 to the Alaska Statutes. The
initiative is almost an exact copy of the California Compassionate Use Act of
1996. Therefore, instead of summarizing the text, I will highlight the dierences
between the Alaska and California texts. The rst dierence is that the Alaska
initiative uses the term cannabis instead of marijuana. Also, in the list of eligible
conditions for which cannabis may be prescribed, the Alaska initiative includes
chronic depression, which the California initiative does not. Furthermore, the
initiative explicitly states that cultivation of cannabis by a patient or primary
health care provider is protected by the Ravin3 decision. Finally, the Alaska
initiative uses the term primary health care provider instead of primary care-
giver. Nevertheless, the denition is the same, except Alaska explicitly includes
licensed home health care workers.
353Ravin v. State, 537 P.2d 494 (1975). In this decision, the Alaska Supreme
Court ruled that under the Alaska Constitution's right to privacy, the state could
not prohibit individuals from smoking marijuana in their homes.
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Discussion
Because the Alaska initiative is almost identical to the California initiative,
one can refer to the discussion of Proposition 215 for a discussion of the Alaska
initiative's text. One must, however, keep in mind that California courts have
written two opinions interpreting the Compassionate Use Act and Alaska courts
could rule a dierent way.
One provision of the Alaska initiative requires discussion. Section 1(d) of
the California initiative exempts patients and their primary caregivers from
state marijuana laws. Section 1(d) of the Alaska initiative exempts patients'
primary health providers, but fails to exempt the patients. Taking the intent
and surrounding text into account, a court will most likely read the clause to also
exempt patients. Nevertheless, this inadvertent omission illustrates the need for
textual precision in drafting. Initiative sponsors need to keep in mind that the
initiative placed on the ballot will become law, even if it includes mistakes.
2. Colorado
Background
The Colorado initiative would amend the state constitution. One of the ini-
tiative's provisions replaces the terms marijuana and marihuana in all Colorado
statutes with the most appropriate of the following terms: cannabis (traditional
marijuana), cannabis concentrate (hashish), or hemp (marijuana stalks and low
THC industrial marijuana).354 The initiative refers to marijuana used for med-
ical purposes as therapeutic cannabis. As a measure of respect for the drafters,
who obviously feel strongly about the terminology, I will refer to marijuana used
for medical purposes as therapeutic cannabis in this section.
354CCCC Colorado xx3(3)(a), 4(l)(a).
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Commission
The initiative creates the Colorado Therapeutic Cannabis Commission (Com-
mission), a seven member commission appointed by the governor.355 The Com-
mission is an administrative body with a broad mandate. It has jurisdiction
over all issues pertaining to therapeutic cannabis,356 and its primary duty is
to implement the initiative.3 ~ In order to accomplish its mandate it can recom-
mend statutory changes,358 promulgate administrative law,359 and enlist the
assistance of other government agencies.360 Furthermore, it has the power to
issue subpoenas, hold hearings, compel testimony and hire experts.361
In addition to general mandates, the Commission has specic duties that
it must fulll. The Commission must develop special rules to regulate ther-
apeutic cannabis use by minors, develop a system for providing amnesty for
patients convicted of therapeutic cannabis use prior to the initiative's pas-
sage, and create penalties for violations of the provisions in the initiative.362
The Commission is also responsible for issuing licenses to therapeutic cannabis
dispensaries,363 which can include state agencies, non prot corporations, physi-
cians or pharmacies.364 For this
355CCCC Colorado x8.
356CCCC Colorado x10.
357CCCC Colorado x9(14).
358CCCC Colorado x9(3).
359CCCC Colorado x9(8).
360CCCC Colorado x 13(2).
361CCCC Colorado x9(9).
362CCCC Colorado x3.
363CCCC Colorado x9(2).
364CCCC Colorado x2(12).
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service it may charge a reasonable licensing fee.365 This licensing clause ap-
pears to provide for buyers clubs in Colorado. Finally, the Commission must
establish discussions between federal agencies, state agencies, and outside par-
ties to establish a cohesive transition where conict of law may exist.366
Patients and Primary Caregivers
The initiative provides an armative defense for any person who reason-
ably believes their actions conform to the requirements of the initiative.367 It
also protects patients and their primary caregivers from arrest, prosecution, or
sanction for using therapeutic cannabis if they have a written recommendation
prescribing therapeutic cannabis from a physician or their medical records in-
dicate such an opinion.368 The medical conditions for which patients may use
marijuana include: conditions such as cancer, AIDS, glaucoma, multiple sclero-
sis, epilepsy, chronic pain, cachexia (wasting syndrome), and nausea caused by
chemotherapy and radiation therapy.
Primary caregivers are dened as adults who have signicant responsibility
for managing the well-being of a patient and who have been designated in writing
as primary caregivers.369 Primary caregivers must possess both a copy of the
patient's written physician recommendation
365CCCC Colorado x9(10).
366CCCC Colorado x9(6).
367CCCC Colorado x5(1).
368CCCC Colorado x6(2).
369CCCC Colorado x6(3).
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or medical records and a document showing their designation as a primary
caregiver.370 A patient may have up to four primary caregivers at one time.37'
Physician Liability
A physician is protected from arrest, prosecution, and sanction for provid-
ing a professional opinion or written documentation that prescribes the use of
therapeutic cannabis for a medical condition.372
Miscellaneous provisions
 The initiative includes various provisions directing how the Col-
orado Attorney General and governor should act.373
 The initiative notes that it is a constitutional amendment and that
all state government agencies must protect and defend the state constitution.
Therefore, they must protect and defend this initiative. It requires state ocer's
who's personal beliefs prevent them from implementing the initiative as their
duties require to resign.374
 Severability clause.3
 The initiative requires that it be liberally construed to achieve its
goals.376
 It is unlawful for individuals to misrepresent their status as eligible
patients.377
370CCCC Colorado x6(3)(f).
371CCCC Colorado x6(3)(b).
372CCCC Colorado x6(1).
373CCCC Colorado xx1 1, 12.
374CCCC Colorado x13(3)(b).
375CCCC Colorado x15.
376CCCC Colorado x16.
377CCCC Colorado x7(2).
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Discussion
This initiative is dicult to interpret. In the areas of patient and primary
caregiver exemption from cannabis laws, I gave what I consider the most rea-
sonable interpretation in light of the wording and declared intent. Other inter-
pretations are possible. For example, a patient may possibly be exempt from
prosecution even without a physician's recommendation. The initiative states
that patients may not be arrested if they are in compliance with the provi-
sions in the initiative and that a physician's recommendation constitutes prima
facie evidence of such compliance. The physician recommendation is not the
requirement, only an evidence of compliance, implying that a physician's rec-
ommendation is not required, only convenient. The initiative, however, does
not indicate what provisions one must be in compliance with.
The initiative's lack of clarity comes from circular denitions. It states that
a patient may lawfully engage in therapeutic cannabis use.378 This sentence
indicates that whether something is lawful depends on whether it qualies as
therapeutic cannabis use. Therapeutic cannabis is dened as cannabis intended
for use in treatment of medical conditions by patients.379 Therapeutic cannabis
use is dened as the lawful use, acquisition, cultivation, possession, or trans-
portation of an adequate supply of therapeutic cannabis by a patient.380 Thus,
whether something constitutes therapeutic cannabis use depends on whether it
is lawful. None of the clauses dene lawful use. This lack of clarity illustrates
the need for care and precision in drafting.
378CCCC Colorado x6(2).
379CCCC Colorado x2(11).
380CCCC Colorado x2(13).
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This initiative seems to be hovering in between requiring a recommendation
and a prescription from physicians, referring to it as a recommendation pre-
scribing therapeutic cannabis.38' Since there is no question that the federal gov-
ernment may take action against physicians who prescribe therapeutic cannabis
and the question regarding whether a physician can recommend it without sanc-
tion is not completely resolved, it is unwise to lean towards requiring a doctor to
do anything that might be construed as a prescription or as assisting a patient
in breaking the law. Some of the other initiatives take a better approach, mov-
ing farther away from any semblance of active encouragement toward a passive
expression of opinion.
The initiative also seems to strike a balance on what medical conditions allow
for the use of therapeutic cannabis. The list of eligible conditions is preceded
by the phrase such as, which indicates that the list is not exhaustive.382 On
the other hand, the list is not open ended because the phrase such as indicates
similarity. Thus other acceptable conditions would need to be similar to the
enumerated conditions, although what conditions would be eligible is not clear.
The drafters should have considered precluding this uncertainty by assigning
the duty of dening eligible conditions to the Commission. Nevertheless, the
wording allows other diseases without opening the initiative up to attacks that
patients with ingrown toenails or simple headaches will be able to use thera-
peutic cannabis.
The initiative also attempts to strike a balance on the distribution problem.
By providing
for a program where the state licenses dispensaries that may sell therapeutic
cannabis, the initiative likely avoids federal pre-emption, but allows some state
control over distributors.383
381CCCC Colorado x6(2)(c).
382CCCC Colorado x 1.
3835ee Section lV.E.2.a. discussing preemption of distribution systems.
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The initiative also authorizes the state of Colorado to create a state agency to
dispense therapeutic cannabis. Although this provision creates supremacy issues
surrounding a state agency violating federal law, the initiative has a potential
safety mechanism to defend against preemption. It requires the Commission
to establish discussions with the federal government to work out a transition
in areas where law conicts. This transition clause may save the distribution
mechanism because the state could argue that the provision does not require
the state to violate federal law, but requires it to seek an agreement with the
federal government. Under such a situation, the distribution system would not
be struck from the initiative, but merely put on hold until the federal govern-
ment relents to permitting buyers clubs. Under this provision, the initiative
avoids preemption, but when the federal government changes its policy, a state
distribution program is in place without the need for additional legislation.
3. Florida Summary384
The initiative allows for patients to use marijuana for medical purposes when
a physician certies that the use is medically appropriate and the patient may
benet. Eligible diseases include: cancer, HIIV, AIDS, anorexia, glaucoma,
arthritis, chronic pain, spasticity, migraine, and any other specied condition,
symptom, or illness. The initiative protects physicians who certify the use
of marijuana from prosecution or discipline. It also protects individuals from
prosecution for cultivation, transportation, provision, or sale of marijuana to
certied patients. The statute does not address primary caregivers; however, the
language indicates that the concept could exist under the proposed section.385
384The text of the Florida is very short. Therefore, I will not footnote the
summary.
385The language in paragraph (d) allows the provision or sale of marijuana
for, or to, a person who has obtained marijuana for certied medical use under
this section. One could interpret
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The initiative authorizes the Florida legislature to implement physician cer-
tication procedures. It also contains a severability clause.
Discussion
The Florida initiative provides a distribution provision by exempting from
marijuana laws the provision and sale of marijuana to qualied patients.386 This
provision could prove politically problematic, but if it receives the necessary
votes, it avoids the preemption danger and provides buyers clubs with much
needed protection.
The initiative also provides for strong physician protection in a unique way.
It used the term certify instead of recommend. Physicians need only certify
that marijuana is medically appropriate and the patient's health may bene-
t. The certication provision moves physicians farther away from the active
endorsement that recommend connotes toward a First Amendment protected
expression of opinion. Nevertheless, certication has an ocial sounding ring
that may help politically.
The drafters big mistake may have been allowing the Florida legislature to
authorize a certication procedure. The lesson leamed from Arizona is that if
the legislature can thwart the law it will. Furthermore, legislation submitted in
California under the guise of clarication actually attempted to make the initia-
tive unworkable.387 The legislature could enact measures requiring a physician's
certication to include a prescription, eectively preventing physicians from cer-
tifying patients. Or the legislature could follow the Arizona route and require
FDA
this section to allow one to possess marijuana for a patient, which would
allow for primary caregivers.
3865ee Section IV.E.2.a. discussing distribution systems.
3875ee Section IV.E.2.d. regarding protecting initiatives from state legisla-
tures.
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approval for certication. The drafters should not trust the legislature to
faithfully execute the initiative.
In addition to these benecial provisions, the Florida statute has two polit-
ical susceptibilities. First, the statute does not address the issue of minors.388
Second, the statute allows marijuana to be used for virtually any illness, leav-
ing it vulnerable to the opponent's' predictions of patients using marijuana
for insignicant ailments.389 Nevertheless, including all diseases is a reasonable
judgement call because it prevents benecial uses discovered in the future from
being prohibited.
4. Maine
~nmm&y
Maine's initiative is one of the shortest and simplest. It enacts 22 Me.
Rev. Stat. 2383-C, permitting a patient or primary caregiver'~ to possess
or cultivate marijuana on the written or oral recommendation of a physician.
It also allows patients to use marijuana if they have been diagnosed with an
illness for which marijuana can provide relief. Physicians are also protected
from punishment or sanction for recommending marijuana to patients. The
initiative does not supersede any law that prohibits dangerous conduct, nor
does it condone marijuana use for non-medical purposes.
The initiative requires the establishment of a seven person study commit-
tee comprised of legislators, proponents of medical marijuana, and the Maine
Attorney General to create a program to supply medical marijuana to patients
who cannot grow their own or do not have a
3885ee Section IV.E. 1.b. discussing the treatment of minors.
3895ee Section IV.E. 1.c.i. discussing limitations on eligible illnesses.
3 ~Primary caregiver means the individual designated by the patient who has
consistently assumed responsibility for the housing, health or safety of that
patient.
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primary caregiver. The program must be implemented within six months of
the initiative's passage.
Discussion
The Maine initiative has two problems similar to California's initiative. It
fails to address the issue of minors, and it includes the provision protecting
patients who use marijuana for personal medicinal use without dening what
personal medical use means.39'
The initiative also takes a unique and potentially controversial position on
when a patient may use marijuana and for what medical conditions. It appears
to allow patients to use marijuana on a doctors recommendation or if they have
been diagnosed with an illness for which marijuana can provide relief. This sec-
ond clause seems to render the rst one unnecessary. If a patient who has been
diagnosed with an eligible condition does not need a doctor's recommendation,
the doctor would have no other reason to recommend marijuana. The initiative
eectively precludes the need for a physician's recommendation and allows self
prescription after an initial diagnosis. Such a situation will raise serious political
issues since opponents will assuredly focus on the fact that a patient does not
even need a physician's approval to use marijuana. To compound the problem,
the list of conditions for which marijuana may be used is also open ended.
In addition to protections for patients, the initiative contains a provision
for distribution. The drawback to this provision is that it requires the state
government to violate federal law.392 State law can legalize distribution without
conicting with federal law, but will conict when the state law requires the
state to act in violation of federal law. Additionally, the initiative faces a
3915ee Section IV.E.2.b. discussing allowable amounts of marijuana.
3925ee Section IV.E.2.a. regarding distribution systems.
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strong danger of federal preemption due to the distribution provision, but
does not contain a
severability clause. Therefore, the entire initiative is at risk of federal pre-
emption. The drafters of the Maine initiative take the position that the federal
government is
wrong, and therefore marijuana activists should not have to appease it. To
them any eorts at incremental advances, compromise, or provisions not fully
directed towards beneting patients constitutes pandering to the federal govern-
ment, police and politicians.393 What they fail to recognize is that an initiative
that seeks to accomplish too much will provide opponents with more leverage in
the election to make the sky is falling arguments that will sway moderate voters.
Furthermore, regardless of why an initiative fails, the federal government will
showcase such failure as proof that the state's citizens do not support medical
marijuana. As I have already argued, failure may harm the movement more
than not trying at all.
393E-mail from Don Christen, Maine Vocals/Maine Citizens for Medical Mar-
ijuana to author (Feb. 14, 1998).
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5. Washington Background
Washington's Initiative 692 adds a new chapter to Title 69 Wash. Rev.
Code. Patients and Primarv Careaivers
Initiative 692 provides an armative defense for any state law relating to
marijuana for qualied patients and primary caregivers.394 To qualify, patients
must meet the following requirements :~
1. Be under the care of a physician;
2. Have been diagnosed with a terminal or debilitating disease;
3. Be a resident of the state of Washington;
4. Have been advised by their physicians about the risks and benets
of using marijuana for medical purposes; and
5. Have been advised by their physicians that they rn~y benet from
using marijuana.
Primary caregivers are dened as adults, designated in writing as primary
caregivers, who are responsible for the housing, health or care of a patient.3 ~
Primary caregivers must posses both documentation certifying the patient as
eligible and written documentation showing their designation as a primary
caregiver.397 They may not consume marijuana (unless they are patients in
as well), or be a primary caregiver to more than one person at a time.398
394Washington Citizens for Medical Rights, Washington, Washington State Medical Use of
Marijuana Act, Initiative 692 x5(1).
395Washington Initiative 692 x6.
396Washington Initiative 692 x6(2).
397Washington Initiative 692 x5(4)(c), (d).
398Washington Initiative 692 x5(4)(d), (e).
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Limitations
Patients and their primary caregivers may not cumulatively possess more
marijuana than is necessary for the patient's personal, medical use, nor more
than a sixty day supply.3 ~ What constitutes a necessary amount is not dened
and presumably depends on each patient's circumstance.
Restrictions on use
It is a misdemeanor to use marijuana in public.400 Patients are also subject to
the normal state laws against driving while under the inuence of marijuana.'9
Furthermore, the initiative does not require employers to accommodate the use
of marijuana at work, on school buses, at school, or at youth centers.402
Physician Liability
The initiative protects physicians from prosecution or sanction for advis-
ing patients about the risks and benets of using marijuana and for providing
a written statement that in the physician's opinion, the potential benets of
marijuana outweigh the health risks for that patientY'3
3 ~Washington Initiative 692 x5(2)(b), (4)(b).
400Washington Initiative 692 x 8(1).
Washington Initiative 692 x8(6).
402Washington Initiative 692 x 8(4). See CMR-Colorado discussion at note
262 regarding the dierence between prohibiting an act versus not requiring
accommodation for an act.
403Washington Initiative 692 x4(5)(a).
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Minors
Minors may use marijuana if they qualify under the normal qualication
requirements.
Parents or guardians, however, must assume responsibility to acquire, posses,
and control usage
of the marijuana to the minor.404
Miscellaneous Provisions
 No property forfeiture is allowed for marijuana use permitted by
this ~
 Health insurance providers are not required to cover the costs of
marijuana.406
 The initiative makes it a class C felony to fraudulently qualify as
a patient eligible to use marijuana.407
 A state may not be held liable for harm incurred by a patient due
to marijuana use for medical purposesY'8
 Severability.409
Denitions
Terminal or debilitating disease means: cancer, HIV, multiple sclerosis,
epilepsy or other seizure disorder, spasticity disorders, intractable pain, and
glaucoma.410 The Washington State Medical Quality Assurance Board may des-
ignate additional qualifying diseases.411
4 ~Washington Initiative 692 x5(3).
405 Washington Initiative 692 x7(1).
406 Washington Initiative 692 x 8(2).
407Washington Initiative 692 x8(5).
408WasH~gton Initiative 692 x7(3).
409Washington Initiative 692 x 10.
410Washington Initiative 692 x6(4).
4t1Washington Initiative 692 xx6(4)(d), 9.
109107
Discussion
The Washington initiative has three constructive provisions that deserve
discussion. First, it takes a moderate approach to dening what medical con-
ditions would qualify for treatment with marijuana. Marijuana use is limited
to enumerated terminal or debilitating conditions, indicating an intent to limit
marijuana use to only serious diseases. This limitation to enumerated condi-
tions will help the initiative politically, preventing opponents from arguing that
marijuana will become available for the simplest problems. On the other hand,
it provides for the Medical Quality Assurance Board to designate additional
qualifying diseases. This approach is a well though out, good balance between
thwarting opponent arguments and providing a method for including additional
conditions that marijuana may prove useful in alleviating.
Second, the initiative avoids placing limits on the amount of marijuana pa-
tients may possess, except that patients may not possess more than a sixty day
supply. This approach to the quantity issue is a good one, similar to AIVIR's
Washington D.C. approach. The initiative is also subject to the same criticism,
however, of not allowing patients enough marijuana to sustain them through
one indoor growing season. Although outdoor grows are feasible in Washington,
voters would surely have more diculty accepting an initiative that permitted
possession of a year's supply of marijuana. Allowing a ninety day supply would
be a reasonable compromise.
Third, the initiative takes a more lenient approach with physicians, similar
to AMIR and Florida. It requires physicians to discuss the risks and benets
of marijuana use with their patients, and then state a medical opinion about
whether the potential benet of marijuana use outweighs the likely risks for that
patient. This provision moves away from the active connotation of the words
prescribe and recommend to a more passive statement of opinion. If courts ul-
timately deem recommending marijuana to constitute a level of encouragement
not
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protected by the First Amendment, a mere discussion of risk and benets
followed by a statement of opinion would most likely remain protected.
In addition to these advantageous provisions, the initiative also includes two
problematic provisions. First, the initiative requires patients to be residents of
Washington.4t2 Requiring some form of Washington identication card may be
an attempt to avoid California's problem of not being able to dene residency.
Nevertheless, a residency requirement may still prejudice long term visitors and
illegal aliens. The initiative is presumably attempting to avoid making Washing-
ton a magnet for out of state residents who want to use marijuana. Nevertheless,
such people are still subject to their state laws when they return home. A better
solution would be to prohibit the export of marijuana from the state, regardless
of whether a patient is eligible to use it or not.
Second, the initiative allows a person to be a primary caregiver to only
one patient at a time. Such a restriction is ill-advised. In People v. Peron,413
California tried assert that primary caregivers may not serve more than one
patient. The court rejected this argument, noting that such a requirement would
prevent individuals from qualifying as a primary caregiver for both mother and
father, or directors of convalescent hospitals or nursing homes from serving as
primary caregivers for more than one resident patient.414 The court found that
such a restriction would unduly burden the goal of the initiative to ensure that
patients have the right to obtain and
4125ee Section IV.E.2.c. regarding limiting eligible patients to state residents.
41359 Cal. App. 4th 1383, 70 Cal. Rptr. 2d 20 (1997).
4t4Idat 1399.
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use marijuana for medical purposes.415 The court's reasoning is the most
powerful argument against limiting primary caregivers to serving one patient.
6. Washington D.C.
Background
ACT UP in Washington, an AIDS activist group in Washington D.C., origi-
nally sponsored Initiative 57 in 1997, but failed to acquire the necessary 17,010
signatures. Initiative 59 is identical to number 57 and is ACT UP's second
attempt in Washington D.C.. Primary Intent
Initiative 59 excepts patients and primary caregivers from the prohibitions
against marijuana possession and cultivation when a physician gives a writ-
ten or oral recommendation that marijuana is medically necessary for the pa-
tient's treatment.4t6 The conditions for which patients may use marijuana in-
clude AIDS, glaucoma, muscle spasm, cancer and any other serious or chronic
illnesses.417 Minors are allowed to use marijuana for medical purposes with writ-
ten consent of a parent or guardian that indicates that the parent understands
the minor's medical condition and the risks and benets of using marijuana
generally and in the minor s situation.4t8
As I noted, primary caregivers who assist individuals with their marijuana
needs are also exempt from marijuana laws. A primary caregiver is dened as
a licensed health care practitioner, relative, domestic partner, case manager, or
close friend who is helping the patient
416ACT UP, Washington D.C. Initiative 59, Legalization of Marijuana for Medical Treatment Initiative of 1998
x2, 6(a).
417ACT UP-D.C. x2.
418ACT UP-D.C. x9.
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with daily needs while the patient is in a weakened state. Patients may have
up to four primary caregivers at one time, and they need not designate their
primary caregivers in writing, although doing so provides prima facie evidence
of such designation.
Limitations
The initiative restricts the amount a patient or primary caregiver may culti-
vate or possess to that which is necessary for a medical supply.419 A medicinal
supply means a sucient quantity to maintain an uninterrupted supply for
treatment.420
Restrictions on use
The initiative does not provide a defense for crimes committed while using
marijuana for medical purposes, nor does marijuana use negate the requisite
mens rea for any defense.421 Distribution of marijuana for non medical purposes
is also prohibited.422
Physician Liability
The initiative protects physicians from prosecution or sanction for recom-
mending marijuana for medical purposes. Physicians required to testify in court
regarding the recommendations may testify before a judge in camera and have
their names kept condential and redacted from public documents.423
419ACT UP-D.C. x6.
420ACT UP-D.C. x6.
421ACT UP-D.C. x4(a).
422D. C. x4(b).
423ACT UP-D.C. x5.
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Distribution
The drafters envision a distribution system involving both government in-
volvement and pnvate actors. They provided a mechanism for distribution
by allowing for the creation of non prot buyers clubs, which may only dis-
tribute marijuana to patients authorized to use it for medical purposes. The
language in this section indicates that the buyers clubs would be required to
verify such authorization through means such as requiring evidence of a doctor's
recommendation.424 Illegal dealers may not use this law as a defense because
it only exempts buyers clubs, patients, and primary caregivers from cultivation
laws. Furthermore, the initiative requires the Washington D.C. Department
of Health Director to develop an aordable distribution plan for all Medicaid
patients and those enrolled in plans funded by the Ryan White CARE Act.425
Miscellaneous provisions
 Severability clause.426 Discussion
ACT UP has developed a number of provisions worth discussing. ACT UP
included a distribution provision and severability clause, which was included in
AMR's Washington D.C. initiative. It is subject to the same praise and criticism
expressed in the discussion of AMR' s Washington D.C., initiative, which for
convenience, this paper repeats in this section. The initiative exempts buyers
clubs from state marijuana laws and it requires the District Department of
Health to develop a distribution plan as well. The exemption for buyers clubs
is not
424ACT UP-D.C. xx6(b), 8.
425ACT UP-D.C. x 10(a).
426ACT UP-D.C. x11.
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susceptible to preemption because it does not conict with federal law.
Therefore, buyers clubs would be exempt from state law, yet still subject to
federal law. The Department of Health distribution plan is a closer call. The
initiative merely requires the Department to develop a plan, so the statute could
avoid preemption under the argument that it requires a plan that does not con-
ict with state law. The plan could be quashed, however, because it would
necessarily cause the District to violate federal law. Nevertheless, the provi-
sion provides the statutory authority to institute a plan as soon as the federal
govermnent alters its policy.
Also, the drafters of Initiative 59 attempted to nd a middle ground in
dening which conditions marijuana may be used for. California's initiative
received harsh criticism for its open ended clause that according to critics al-
lowed marijuana to be used for virtually any problem or discomfort. Initiative
59 maintained a general savings clause but restricts the qualifying conditions
to serious and chronic.
Another good provision prevents defendants from claiming that being high
on marijuana, justied under state law, prevented them from developing the
requisite mens rea to commit a crime. If criminals were gaining refuge under
a medical marijuana law, it would quickly lose much of the support it enjoyed
during the elections. A number of initiatives have praiseworthy provisions that
expressly disavow protection for driving or engaging in other dangerous acts
while using marijuana; however, Washington D.C. is the only one that addresses
the potential argument that patients using marijuana may not be responsible
for their actions.
Finally, the drafters came up with an ingenious way of protecting doctors.
Doctors may testify in camera regarding their marijuana recommendations to
patients, and have their names kept condential. While the federal government
could easily ascertain the doctors' names in the course of a criminal investiga-
tion, doctors have plenty of other reasons to remain anonymous.
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Doctors fear retribution from a number of sources: professional organiza-
tions, colleagues, the
District, and the federal government. If doctors must be afraid few will
recommend marijuana.
VI. Conclusion
When the medical marijuana advocacy movement shifted its focus to state
initiatives, many people decried this strategy as a surreptitious attempt to com-
pletely legalize drugs. They accused drug legalization supporters of using people
aicted with cancer and AIDS as pawns to further their agenda. To bolster
their assertions, opponents pointed out that the initiatives did not even require
a prescription or FDA approval. They argued that the United States has a
system in place to protect patients from snake oil and harmful drugs and that
voters should not jeopardize the health of patients by subverting this system.
Some opponents may believe these arguments, which might be valid if the
United States drug approval system was not awed, both technically and po-
litically, in such a manner that prevents the approval of marijuana even if it
does have medical benets. Granted, marijuana legalization activists naturally
supported the initiatives, but so did patients, physicians, nurses, and groups
such as ACT UP who do not have a unied opinion regarding drug legalization.
They merely recognize the overwhelming anecdotal evidence{through their nu-
merous rst hand experiences{that marijuana does help ill patients in certain
instances where nothing else does, and in other cases it helps them with fewer
negative side aects than traditional drugs. In order to deal with federal laws
that continue to prohibit medical uses of marijuana, initiative drafters had to
write them in a manner that is concededly less than ideal. Nevertheless, these
provisions, such as not requiring a doctor's prescription, are rational provisions
intended to provide some measure of regulation, and not to legalize marijuana
for all.
Over the last twenty-ve years, marijuana advocates have sought to obtain
patient access to marijuana. During these twenty-ve years, the government
maintained a position that existing scientic evidence did not support approval
of marijuana for medical uses, while thwarting
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eorts to perform scientic studies that might show medical benets. Notwith-
standing the government's resistance to using marijuana as medicine, polls and
surveys indicated that the general public supported such use. Therefore, redi-
recting their eorts to state voter initiatives was a natural and reasonable strat-
egy. Even if marijuana ultimately proves medically useless, state initiative pro-
ponents are not misguided. Not only can they not currently prove marijuana's
medical ecacy according to contemporary scientic standards, neither can op-
ponents prove that it is not ecacious. It is not misguided to demand that the
question be answered.
Until the federal government gives in to the pressure created by states who
pass medical marijuana initiatives and allows the traditional drug approval pro-
cess to function as it was intended, medical marijuana advocates have no other
option than to continue their state eorts through both voter initiatives and
state legislatures. California's Proposition 215 demonstrated the wisdom of
medical marijuana advocates' choice to redirect their eorts toward the states.
Since its passage, the federal government has instituted a study to determine
what evidence pertaining to marijuana's medical ecacy currently exists, and
has provided not only the marijuana, but a million dollar grant for the study
that it spent years trying to thwart.
For those who wish to draft voter initiatives, this paper critiques past and
present initiatives with the goal of providing future drafters with a guide so
they do not have to start from scratch. Because various groups have dier-
ent goals and priorities, no ideal initiative exists. Nevertheless, certain issues
transcend diverse goals. Regardless of whether the drafter's goal is to pass the
rst initiative in a step-by-step approach, to pass one that will pressure the
federal government politically or through additional pressure on its law enforce-
ment capabilities, or to provide the best initiative for the patients, analyzing
other initiatives and the subsequent developments of those that have passed is
imperative.
117